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GENERAL INTRODUCTION 
9 
1.1 PRIMARY BILIARY CIRRHOSIS 
Primary Biliary Cirrhosis (PBe) is a chronic, cholestatic liver 
disease characterized by non-suppurative destruction of interlobular and 
septal bile ducts, with subsequent liver damage and eventually 
development of cirrhosis (1). The disease is relatively rare with an 
estimated annual incidence and point prevalence in Europe of about 14 
and 114 per million population respectively (2).The course of the 
disease is variable and unpredictable, but potentially f.1tal. 
Clillical featllyes alld lIatllral COllyse. 
Over 90% percent of the patients are female, predominantly in 
their middle ages. Pruritus and fatigue are the most common symptoms 
and are present in about one third of the patients at presentation. 
Nowadays,jaundice (ca. 4-20%) and other complications of liver 
diseases e.g ascites and variceal bleeding (ca. 5%) are rather unusual at 
presentation, but may develop later on (3,4). Other symptoms regularly 
appearing in the course of the disease are right upper abdominal pain, 
hepatosplenomegaly, hyperpigmentia and xanthelasmas. 
PBC is associated with other disorders, mostly of autoimmune 
origin, like Raynauds syndrome, sclerodennia, CREST syndrome, 
hypothyroidism, arthropathy (mainly arthralgias, rarely fi:ank arthritis) 
and, most fi'equently, the sicca syndrome. Patients are frequently 
recognized in the evaluation of these disorders (1,3,4). Furthermore, 
persistent pruritus after gravidity may indicate PBC (1). 
The clinical presentation ofPBC has changed during the last 
decades (5). In 1959, Sherlock reported that 86% of the PBC patients 
presented with symptoms and a similar percentage was found in a 
group observed in the sixties (6,7). In contrast, studies in the eighties 
reported about 30% of the patients to be symptomatic at entry (3,4,8). 
This increasing recognition ofPBC in an earlier, asymptomatic stage is 
probably due to more frequent routine biochemical screening, the 
increased availability of assays for antimitochondrial antbodies and 
greater awareness of the disease (2). Although 5-year survival after 
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diagnosis remained unchanged (80%), lO-year survival was 20% in the 
fifties (5,9) compared to over 50% in more recent series (3,10-12). 
Earlier detection of PBe may have attributed to this change in the 
long-term prognosis of PBe patients as a group. 
Life expectancy is better in patients asymptomatic at presentation 
than in those who are symptomatic (median 16 years versus 7.5 years 
(13)), though worse than for a normal age and sex matched population 
(8,13,14). Once patients develop symptoms the disease runs a course 
comparable to that of symptomatic patients (8,13). The reported 
frequencies of asymptomatic patients developing symptoms (i.e. 
pruritus, fatigue, edema, complications of cirrhosis) are variable 
(3,8,13,14). The majority of the studies indicate that about 40% of the 
patients will become symptomatic after a median follow-up of ca. 10 
years (3,8,13); this percentage rises to 64% after a median follow-up 
period of 15 years (13). 
Bioc1temical featllres. 
PBe is characterized by a cholestatic liver test profile, i.e. raised 
serum alkaline phosphatase and y-GT with normal or moderately 
increased transaminases. Bilirubin may be normal or increased. In about 
90% of the patients immunoglobulin M is elevated (15). Furthermore 
cholesterol levels are often high (1). This docs not seem to be associated 
with a higher mortality due to atherosclerosis, probably because of the 
elevated high density lipoprotein concentrations in PBe (16,17). 
The most important diagnostic serological marker is the presence 
of antimitochondrial antibodies (AMA), found in 95% of the patients. 
Recent research has disclosed the antigenic site of the PBe specific 
antibodies (labeled M2) which is the E2 subunit of the 2-oxo-acid 
dehydrogenase complex located on the inner mitochondrial membrane 
(18). The relation between disease progression and M2 levels is still 
controversial (19,20). One study showed the presence ofE2 antibodies 
on biliary epithelial membranes of PBe patients, but not in controls 
(21). Previously, cross-reactivity of AMA with antigens on the surface 
of a variety of other cells in PBe had already been found (22). Up till 
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now, it is still unclear whether the presence of AMA is of pathophy-
siological significance or an epiphenomenon with only diagnostic 
importance. Interestingly, based on the presence of other types of 
antimitochondrial antibodies, the possibility to differentiate early in the 
disease between patients with a benign (M9 antibodies) or progressive 
course (M4 and M8 antibodies) has been suggested by one group (23). 
This finding as well as the identities of M4 and M9 antibodies, 
however, have not been confirmed by others (24). 
Recently some workers (25-28) have compared the features of 
AMA positive with those of AMA negative patients, for which the term 
"autoimmune cholangiopathy" has been coined (28). The currently 
available data do not indicate any m'\ior differences between these 
patient groups with respect to clinical, biochemical and histological 
features, except for the higher incidence of antinuclear and smooth 
muscle antibodies and lower IgM levels in the AMA negative group. 
Whether these groups differ in natural history and response to 
treatment remains to be established. 
Histological features 
The characteristic histological lesion ofPBC is the destruction of 
septal and interlobular bile ducts by predominantly mononuclear cell 
infiltrates (florid duct lesion), often associated with granuloma 
formation. This leads to ductopenia, progressive cholestasis, liver cell 
damage, fibrosis and ultimately biliary cirrhosis. However, the florid 
duct lesion and granulomas are often not identified, partly due to the 
focal character of the disease. Ductopenia, with or without copper 
accumulation secondary to cholestasis, may then be highly suggestive, 
though not specific, for PBC (29). 
PBC can histologically be staged according to the method 
proposed by Scheuer (30), which was slightly modified by Ludwig (31) 
(table 1). 
It should be born in mind that currently only 20-45% of the 
patients have cirrhosis at the time of diagnosis and the term "primary 
biliary cirrhosis" is therefore incorrect and misleading (3,8,13) 
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Table 1. Histological stages ofPBC (31) 
Stage I Portal hepatitis with little or no periportal inflammation or 
piece meal necrosis. 
Stage II Periportal hepatitis, usually with piece meal necrosis. 
Stage III Presence of bridging necrosis or septal fibrosis or both. 
Stage IV Cirrhosis with fibrous septa and nodular regeneration. 
Pathogetlesis 
The etiology of the disease is still unclear. PEC is increasingly 
considered to be an auto-immune disorder as suggested by the presence 
of autoantibodies, particularly 'llltimitochondrial antibodies, and multi-
ple other humoral and cellular immunological aberrations including 
increased IgM, complement system activation, circulating immune 
complex-like material which is ineffectively cleared by Kupffer cells 
and functional defects ofT-lymphocytes and natural killer cells such as 
reduced lymphokine production (32-36). Histologically, PBC resembles 
the lesions observed in immunological disorders like graft versus host 
disease and chronic rejection of a liver transplant (37,38). Increased 
HLA-I antigens on bile duct and liver cells and the aberrant expression 
ofHLA-II antigens (39-41), as well as the presence of intercellular 
adhesion molecules (particularly ICAM-i), which are essential in theT 
lymphocyt-target cell interaction, on biliary epithelium (42) and in 
serum (43) also suggest an immunological pathogenesis. Furthermore 
the predominance of the disease in women and the association with 
other autoimmune diseases strengthen the concept of an autoimmune 
genesIs. 
Genetic £:1Ctors may also playa role in PEe. Recently, genotypic 
HLA typing methods have confirmed the association with HLA-DR8 
as previously noted by phenotypic methods (44-46).Also associations 
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with several MHC Class-III profiles, encoding complement 
components, have been reported, although not consistently (47,48). 
Furthermore £1miliar PBC has been reported in 2-4% of the patients 
(2,49), and decreased in vitro suppressor lymphocyte responses have 
been found in PBC patients as well as in their [1mily members (50). 
The pathogenesis of PBC appears to be multifactorial. 
Supposedly, an at present unknown exogenous [1ctor triggers the 
immune action directed at the biliary epithelium in predisposed pers-
ons, as may be indicated by the above mentioned HLA associations and 
abnormalities in suppressor cell function and complement action (51). 
An infectious etiology has been postulated, because in close contacts, 
relatives and laboratory personel working with PBC blood, as well as 
during viral infections "naturally occurring antimitochondrial 
antibodies" (NOMA) have been found. However, these NOMA differ 
from PBC specific AMA and are rarely present in PBC patients (52). 
Furthermore cross-reactions between mitochondrial antigens and 
membrane components ofE. Coli Rough mutants have been 
documented (53,54). In addition, it was shown that 69% of healthy 
controls with recurrent urinary tract infections show weak mitochon-
drial antibody reactivity, while Rough bacteria forms were present in 
equal percentages (40%) of controls and PBC patients with recurrent 
urinary tract infections (55). 
More recently a similar cross-reactivity has been found for 
Mycobacterium Gordonae, which is particularly interesting in view of 
the granulomatous character ofPBC (56).Although these findings 
suggest a possible etiological role of these micro-organisms and add to 
the hope on future unravelling of the PBC enigma, up to now no 
convincing evidence has been established. 
Subsequent to the primary immunological destruction of bile 
ducts, irreversible bile duct loss leads to cholestasis and accumulation of 
hepatotoxic primary bile salts such as chenodem,:ycholic acid, which is 
supposed to cause further liver damage (57,58). 
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Progllosis 
Before the advent of the liver transplantation in the beginning of 
the eighties the ultimate outcome of the disease was fatal in most cases. 
Liver transplantation, however, has drastically changed this grim 
prospect. Currently it is the only curative treatment for (end-stage) 
PBC, with 1- and 5-year survival rates of about 75% and 70% 
respectively (59). Recurrence ofPBC after transplantation has been 
suggested by several groups (60-62). Difficulties in differentiating PBC-
related lesions from features of chronic rejection preclude definite 
conclusions (63,64). Clinically manifest disease recurrence has not been 
reported. 
The success ofJiver transplantation is greatly influenced by the 
disease state at referral, those with least advanced disease £1ring best 
(65). Models predicting prognosis may optimalize the decision making 
on who and when to operate. The (ongoing) development of such 
models using Cox regression analysis (66-68), recently culminated in 
sophisticated models which offer the possibility to adjust the estimated 
prognosis during the course of the disease (69,70). However, the cur-
rent models may not be applicable in individual patients and in patients 
under treatment and further validation and refinement is needed (71). 
1.2 THE TREATMENT OF PBC - A.D. 1990 
For end-stage PBC liver transplantation has become an effective 
treatment. However, medical treatment, aiming at the prevention of 
disease progression in patients with non-advanced disease has been 
disappointing. Cupruretic (72-79), antifibrotic (80-82), anti-inflamma-
tory and inmltlnosuppressive (67,83-87) drugs have been evaluated and 
were found to be unable to halt disease progression or to be too 
harmful.These trials have been reviewed in extenso by others (1,51,88) 
and are summarized in table 2. During the eighties, reports on treat-
ment with ursodeo,,!,cholic acid emerged and gave new hope to 
workers in the PBC field and their patients. 
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Table 2. Controlled drug trials in Primary Biliary Cirrhosis, other than ursodeoxycholic acid: effects on 
symptoms, liver tests, histology and survivaL The degree of intolerance to the drug has been estimated, based on 
the percentage of withdrawals/drop-outs in the treatment group as compared to the placebo group (++ = >10% 
and >2x the percentage in the placebo group; + = >10% and >1.5x ; - = ::::; 10% or :0.5 x) 
Drug No. of Total no. Improvement in Intolerance 
(ref) studies patients symptoms liver functions histology survival 
Penicillamine 8 740 ± ++ 
(72-79) 
Colchicine 3 181 ± ± + 
(80-82) 
Chlorambucil 1 24 n.e. + n.e. ++ 
(84) 
Cyclosporin 2 41 ± + n.e. + 
(85,86) 
Prednisolone1 1 36 + + + n.e. - (10mg/d for 1yr) 
(87) 
Azathioprine1 2 45 ± ± + (2mg/kg/d for 1-6 yr') 
(83) 
(67) 248 + +' - (lmg/kg/d for 6-12 yr') 
(5 yr: 41% it) 
n.e. = not evaluable/evaluated + = improvement ± = trend or not consistent - = no improvement ! t = reduction in death 
1 presented more eA."plicitly in view of the importance for this thesis: 2 after adjustment for unequal bilirubin levels at entry 
UrsodeOX1'c1/O/ic acid 
In 1981, Leuschner et al. first noted that ursodeoA),cholic acid 
improved transaminases in patients suffering from both chronic active 
hepatitis and gallstones (89,90). Soon thereafter, Poupon et al. reported 
the first uncontrolled data in PEC patients showing similar 
improvements in standard liver tests as well as pruritus (91). Subsequent 
small controlled trials (92-94) were all encouraging and in agreement 
with the results of the first large randomized placebo-controlled trial 
published by Poupon et al. (95) in 1991 (table 3). 
Poupon found improvements in fatigue and pruritus which 
tended to be greater in the treatment group, although they did not 
reach significance in the intention to treat analysis. UDCA clearly 
decreased the levels of bilirubin, liver enzymes, IgM and antimitochon-
drial antibodies. Furthermore, improvement of histological, inflam-
matory features but no effect on fibrosis was noted in the UDCA 
group. Although these studies did not show serious side effects, some 
authors warned that ursodeoxycholic acid may not only be ineffective 
but could even be toxic in PBC patients with stage IV disease (96-98). 
UDCA is the 7p epimer of chenodeoA),cholic acid with the 
chemical structure 3a7P-dihydroA),-5p-cholan-24-oic acid and is 
naturally occurring in the human bile acid pool in small quantities 
«4%) (58). In Asia, for ages already, healing properties in chronic liver 
disease have been ascribed to the bile of the black bear, which contains 
large amounts of UDCA (99). 
Several mechanisms of action were considered to be of 
importance in the treatment of PEC with UDCA. Hydrophobic bile 
acids are more damaging to cells than hydrophilic bile acids. Compared 
to the more abundant endogenous bile acids, UDCA is less hydropho-
bic, has a higher critical micellar concentration and lower cell surface 
activity. These properties result in a lower cell damaging capacity (58). 
Therefore enrichment of the bile acid pool with UDCA at the expense 
of hydrophobic bile acids is likely to reduce hepatic damage. During 
UDCA treatment the proportion ofUDCA in bile and serum indeed 
rises to over 50% (58,100) and it has been shown that UDCA decreases 
17 
Table 3. Controlled trials with ursodeoxycholic acid in Primary Biliary Cirrhosis 
Author Dose No. of Follow Symptoms Liver Histology Signs of Survival/ 
year patients up functions infiammationifibrosis progression l liverTx 
(ref.) (mg/day) (n= ) (months) [bilirubin] 
Leuschner 10/kg 20 9 ± + [n.e.] ± /- n.e. n.e. 
1989 (92) 
Oka 600 45 6 + [-] n.e In.e. n.e. 
1990 (93) 
>-' 
00 Hadzyannis 12-15/kg 50 29 + + [±] - /- -/-
1991 (94) 
Poupon 13-15/kg 146 24 ± + [+] + /- + -/-
1991 (95) 
n.e. ::::;; not evaluable/evaluated + - improvement ± - trend or not consistent - = no improvement 
1 signs of progression: hepatic decompensation e.g. ascites, variceal bleeding, encephalopathy 
the reabsorption of endogenous bile acids from the gut (101-103). 
However, several workers found the decrease in endogenous bile acids 
to be mainly at the expense of cholic acid, a relatively hydrophilic bile 
acid, while chenodem .. ycholic acid, the main hydrophobic constituent 
of the bile acid pool, remained unaltered (101,104). Whether UDCA 
produced a net shift towards hydrophilicity in the bile acid pool was 
therefore still unclear. 
Another potential mechanism of action is the enhancement of 
bile flow by UDCA as has been found in rats. This is probably due to 
the existence of a cholehepatic shunt in which the unconjugated form 
ofUDCA in bile becomes protonated by H,CO, (leading to increased 
biliary HC03- excretion), and thus becomes more lipophilic. This 
makes UDCA more easily reabsorbed by the biliary epitheliary cells 
after which it can be resecreted again by the hepatocytes (105,106). 
UDCA may have more direct, hepatoprotective effects. It has 
been shown that UDCA reduces the cytolysis induced by other, 
hydrophobic bile salts (107-109). Furthermore it was suggested that 
UDCA might also have immunomodulating properties because UDCA 
reduced elevated serum IgM levels (95) as well as the aberrant 
expression of HLA I on hepatocytes (110), although this might be an 
effect secondary to reduced cholestasis (111). 
COllsideratiolls 011 fllrt/ler treattUeIlt of PBC 
No data concerning the effect ofUDCA on disease progression 
were available in the beginning of the nineties. However, presuming 
that UDCA mainly interferes with bile acid mediated liver damage 
secondary to cholestasis, we considered it unlikely that UDCA alone 
would lead to an inactivation of the disease in a substantial number of 
patients during short term treatment and to a major slowing of disease 
progression in the long run. We reasoned that the combination of 
UDCA with other potentially effective drugs would be more 
appropiate to reach these aims (112).Therefore studies evaluating 
additional treatment options in patients who would not achieve a 
complete disease remission on UDCA alone were considered a logical 
next step. 
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Regarding the supposed pathophysiology of PBC the 
combination of UDCA (mainly protecting the liver £i'om bile acid 
toxicity) with immunosuppressive drugs directed at the alleged 
autoimmune attack seems logical (112,113) while another attractive 
avenue would be the additional use of antifibrotic drugs like colchicine. 
A number of drugs have been shown to delay disease progression 
to some extent or at least to ameliorate liver function abnormalities, 
which could be candidates to be added to UDCA treatment. The 
toxicity of the immunosuppressive drugs chlorambucil and cyclospo-
rine, outweighed their beneficial effects and they were therefore 
considered less suitable options (84,86,87,114). 
Limited uncontrolled data indicated a possible beneficial effect 
(115,116) oflow dose methotrexate (15 mg/week) in PBe. However, 
methotrexate may have potential severe adverse effects such as 
hepatotoxicity, interstitial pneumonitis and cytopenia and was therefore 
considered less appropiate (117,118). 
Colchicine, a drug with anti-inflammatory and antifibrotic 
properties, is well tolerated and has been shown to improve 
biochemistry in PBe. Though some studies suggested a reduced 
progression (80,82), long term follow up did not show an effect on 
survival or need of liver transplantation (119). Furthermore a treatment 
directed against the primary cause ofliver damage (autoimmune attack) 
was considered more attractive than one directed mainly at a mecha-
nism secondary to hepatic damage i.e. fibrogenesis. 
Corticosteroids, the mainstay in the treatment of many immune 
disorders has long been considered contraindicated in PBC, due to fear 
of its deteriorative effects on the bone status, particularly because 
osteoporosis is already associated with PBC (29,120). Early 
uncontrolled experience with corticosteroids in PBC patients with 
advanced disease and jaundice fed this fear (9,121). 
In our centre, uncontrolled studies evaluating prednisone in 
combination with cyclosporine indicated the potential benefit of 
.corticosteroids in PBC (51) and recently, Mitchison et a1. (88) for the 
first time evaluated the effects oflow dose corticosteroids in a placebo-
controlled study. They found improvements in biochemical activity 
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parameters as well as in procoliagen-Ill propeptide, a marker of active 
fibrogenesis (122) and liver biopsy features. However, the rate of bone 
loss doubled during the first year of treatment. 
It is well known that steroid induced bone loss is highest during 
the first year of treatment (123,124) and recent studies have indicated 
that the long term use oflow dosages of corticosteroids is not associated 
with major deterioration of bone status (125,126). Furthermore, the 
risk of steroid-induced bone loss may be a manageable adverse effect, 
by using preventive measures such as bisphosphonates (127). 
Like prednisone, azathioprine has been used as an 
immunosuppressive drug on a large scale since several decades. In PBC, 
two controlled studies with azathioprine have been performed. In the 
largest and longest trial a small improvement of survival was noted (67), 
although effects on biochemistry and symptoms were minor (83). 
The USe of azathioprine in PBC has been limited mainly by the 
fear for an increased risk of malignancies. This risk seems to be vety 
small and has been mainly documented during the use of high doses of 
azathioprine in post transplant patients (128). Nowadays, there is vast 
experience with the combination of prednisone and azathioprine in 
another autoinm1l1ne liver disease i.e. chronic autoimmune hepatitis, in 
which this combination has been effectively used during more than 20 
years (129, 130). Long term follow-up of patients with chronic auto-
immune hepatitis, who were treated with prednisone and azathioprine 
showed only a very slight increase in extrahepatic malignancies as 
compared to a normal population (131). 
The drugs have a mutual dose sparing effect and therefore a 
decrease in the risk of adverse effects and an increase in inm1l1no-
suppressive potential may be achieved by combining low doses of 
prednisone and azathioprine in PBe. 
Clinical investigations in PBC during the last 10-15 years 
(51,132), have raised several questions. The Dutch Multicenter PBC 
Project, initiated in 1990, offered the opportunity to study some of 
these questions. This thesis contains the current results of this ongoing 
project. 
21 
1.3 AIMS OF THIS THESIS 
1. To determine how many PEC patients achieve complete 
disease remission during 1 year of ursodeoA!,cholic acid 
(UDCA) therapy. 
2. To assess whether patients with compensated stage IV PEC 
respond less to, or may even deteriorate by UDCA treatment. 
3. To compare single dose and multiple dose UDCA treatment 
with respect to their effects on biliary UDCA enrichment and 
biochemical response. 
4. To study the effects of prednisone/azathioprine or placebo in 
addition to UDCA with regard to symptoms, serological 
parameters of cholestasis, liver damage, fibrogenesis and 
inm1Une activity, and histology. 
5. To investigate whether bone loss in corticosteroid treated 
PEC patients can be reduced by cyclical etidronate. 
6. To assess whether the short term benefit-risk ratio of 
prednisone/azathioprine treatment in addition to UDCA 
justifies larger, long term studies with this therapeutic 
regimen. 
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SUMMARY 
To assess the potential of ursodeQ)(ycholic acid (UDCA) to induce 
complete remissions in Primary Biliary Cirrhosis (PBC) 110 patients 
with non-advanced PBC entered an open, prospective, multicentre 
study. 
Complete remission was defined as symptomatic remission (no 
pruritus and fatigue), biochemical remission (normal bilirubin, 
aspartate aminotransferase and IgM and alkaline phosphatase :s 1.5 times 
the upper limit of normal) and histological remission (no inflammation 
beyond portal tracts and no active bile duct destruction). 
Within 1 year the prevalence of abnormal biochemical parame-
ters as well as the prevalence of pruritus and fatigue decreased 
significantly. Twelve patients attained a biochemical remission. Seven 
achieved a biochemical illld symptomatic remission. In 6 of these 7 
patients a liver biopsy could be performed. The criteria for histological 
remission were fulfilled in 3 of them. 
In conclusion, complete remission is achieved in at most 4% (95% 
CI: 0-8%) of the patients with non-advanced PBC during UDCA 
treatment within 1 year. To induce complete inactivation of the disease, 
combined treatment of UDCA with other drugs appears necessary. 
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INTRODUCTION 
Primary Biliary Cirrhosis (PBC) is a usually slowly progressive 
disease of unknown cause with many features of an autoimmune dis-
order. Initially there is mainly involvement of the small intrahepatic bile 
ducts, in the later stages progressive fibrosis and ultimately cirrhosis 
with secondary copper overload may develop (1). 
Ursodem.:ycholic acid (UDCA) is nowadays increasingly consi-
dered as the first-line treatment option for PBe. Despite numerous 
studies the precise mode of action ofUDCA remains unclear, and 
beside replacement of toxic endogenous bile acids by UDCA (2), 
hepatoprotective (3-5), hypercholeretic (6), and immunological (7,8) 
mechanisms may be involved. 
Several controlled trials have shown clear beneficial effects of 
UDCA on biochemical and immunological parameters of the disease 
(9-14). Uncontrolled studies suggested impressive improvement in 
complaints, but this effect was less convincing in controlled studies 
(9,14). Some studies have also indicated improvement in liver histology 
(9,10). Reports of up to 4 years of placebo-controlled follow-up did 
not show clear improvements in survival (15-17), although in one study 
significantly less liver transplants were performed in patients receiving 
UDCA during 4 years compared to patients with 2 years ofUDCA 
(17). Current data suggest that UDCA slows down the progression of 
the disease but does not seem capable to induce a complete inactivation 
of the disease in most patients. It seems likely that any drug which 
potentially could alter the natural course of the disease should exert 
marked effects on clinical, biochemical and histological parameters. In 
analogy with other autoimmune diseases, e.g. chronic active auto-
immune hepatitis, disease remission has therefore been proposed as the 
first and main treatment goal in PBC (18,19). Surprisingly, no studies 
have been published evaluating the potential ofUDCA to induce 
disease remission. This prospective study was initiated to assess how 
many patients with PBC achieve a complete (symptomatic, biochemi-
cal and histological) remission during UDCA treatment. 
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PATIENTS AND METHODS 
In October 1990 a prospective multicentre study was initiated in 
the Netherlands to evaluate new treatments in PBC. The design of this 
project aims to reflect the general therapeutic approach to diseases for 
which no established effective treatment is available: patients are first 
treated with the current best mono therapy and when this is not suffi-
ciently effective are offered an alternative (or additional) treatment. 
Patients who do not satisfactorily respond to the standard therapy, ill 
caslI UDCA, are candidate for subsequent enrollment in controlled 
evaluations of additional, new treatment options. Up till now 160 
patients in 30 centres (4 university and 26 non-university clinics) are 
participating in this project. 
The first 110 patients completing the first phase of the project, 
i.e. an open 1 year study with UDCA, are subject of this report. Before 
the start of the study it was determined that the first evaluation would 
be performed as soon as the complete follow-up data of at least 100 
patients would be available. 
Palietlt selecliotl 
Newly diagnosed patients as well as patients with a longer-
standing diagnosis of PBC were included. Patients who were already 
being treated with UDCA were withdrawn from this treatment for at 
least 3 months before entry. 
PBC was diagnosed when 2 m'\ior and 2 minor diagnostic crite-
ria or 1 m'\ior and 4 minor criteria, according to Taal et aI., were 
present (20). Major criteria are: a level of antimitochondrial antibodies 
1120 and a liver biopsy showing duct lesions. Minor criteria are: 
pruritus,jaundice with normal clotting factors, alkaline phosphatase 
,=2 x upper limit of normal, serum IgM above normal, a Schirmer test 
showing < 10 nUll tear secretion in 5 minutes. Exclusion criteria were: 
age >75 years, presence of another life expectancy limiting disease, 
evidence of extrahepatic bile duct disease on ultrasound, pregnancy or 
risk of pregnancy due to lack of suitable contraception, absence of 
manifest disease (= fulfillment of criteria for complete response - see 
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below) and the use ofUDCA within 3 months prior to entry. 
Furthermore patients with advanced disease (Child-Pugh class B or C) 
were excluded as these patients are likely candidates for liver trans-
plantation in the near future and in general seem unlikely to benefit 
fi'ommedical treatment (19). 
Study design 
Patients received UDCA (Ursochol® 300 mg tablets; Zambon 
B. V., Amersfoort, The Netherlands) in a single late evening gift. The 
dose was adjusted according to body-weight: 450 mg if < 50 kg, 600 
mg if 50-70 kg and 750 mg if> 70 kg, thus corresponding to ± 10 mg! 
kg daily. 
At entry and at 3-monthly follow-np visits a clinical examination 
was performed, including assessment of pruritus and fatigue as either 
being absent or present, and laboratory investigations (bilirubin, 
alkaline phosphatase (APh), aspartate aminotransferases (AST), IgM). 
Furthermore creatinine, albumin, Hb, WBC, platelets, prothrombin 
time, and antithrombin-III were measured at entry. 
For all patients admitted to the study liver biopsies were available 
for diagnostic review. Considering the non-controlled design of the 
study it was decided not to insist on performing a new liver biopsy at 
entry. For this study, evaluation of repeat biopsies was only demanded 
in patients who had attained both symptomatic and biochemical 
remission after 1 year of UDCA, as it is unlikely that patients with 
clinical disease activity will have a histological remission. All biopsies 
were reviewed by one pathologist (FTJW ten K), who was not aware of 
the clinical results. 
Definitions for remission as proposed by Beukers and Schalm 
were used (19). These include disappearance ofPBC-reiated complaints, 
especially pruritus and L1tigue, (symptomatic remissioll); normal values for 
bilirubin, AST and IgM, with APh not exceeding 1.5 x the upper limit 
of normal (biochemical remissioll), and inflammatOlY infiltrate absent or 
restricted to the portal tracts without bile duct destruction and absence 
of granulomas (ilistological remissioll). Complete remissioll was defined as 
symptomatic, biochemical and histological remission. 
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A steering committee was established to address scientific, metho-
dological and ethical problems arising during the study. Informed 
consent was obtained from each patient and the study was approved by 
all local ethical committees. 
Statistical at/alysis 
Quantitative data are expressed as multiples of the upper limit of 
normal (ULN) of each centre. Differences between the levels at entry 
and after 1 year were analysed using the Wilcoxon's signed rank test. 
Differences in the number of patients with abnormal parameters and 
complaints between entry and 1 year were compared by the 
McNemar's-test.A p-value :s0.05 was considered significant. 
Table 1. Patient characteristics at entry. 
No. of patients: 
Median [range) age (yrs) 
Median [range) disease 
duration (yrs): 
No. of males: 
Histology 
Cirrhosis 1: 
No cirrhosis2 : 
No recent data: 
Patients 
included 
110 
58 [33-75) 
5 [0-19) 
14 (13%) 
20 (18%) 
38 (35%) 
52 (48%) 
As histologically documented previously. 
Liver biopsy performed < 1 year before cntry. 
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Patients 
evaluated 
104 
58 [33-75) 
5 [0-17) 
14 (14%) 
20 (19%) 
38 (37%) 
46 (44%) 
RESULTS 
At the time of evaluation 104 of the 110 included patients had 
completed one year of treatment with UDCA . Six patients stopped 
treatment and were excluded from analysis. Four of them stopped 
UDCA treatment because of supposed adverse effects: three patients 
experienced abdominal discomfort (nausea, vomiting) and one had 
increased itching, fatigue and malaise not responding to dose reduction; 
two asymptomatic patients were no longer motivated to continue the 
medication. In 5 of the 6 patients, biochemical abnormalities clearly 
improved during UDCA and deteriorated after withdrawal. None of 
them attained a spontaneous clinical remission. The main entry 
characteristics of the 110 included as well as the 104 evaluated patients 
are given in table 1. 
x ULN 
4.5 -
"'1==:::::.i~"""""+O::::::::::~ AP h 
2~ L IgM 
1.5- ~ 
~--~I~--~l-----'lAST ~~-----'!~--~----~t----~ 
. f 11 Bilirubin 
0.5 -
Okl ____ ~------L-----~----~ 
o 3 6 9 12 
months 
Figure 1. 
Mean levels ofbilirubin,APh,AST and IgM in 104 patients completing 1 yeJr ofUDCA treatment. Tile 
bars indicate the standard error of the mean. All parameters improved significantly (bilirubin p=O.02, all 
other parameters p<O.OOt). 
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Symptomatic remission 
The numbers and percentages of patients with pruritus and 
fatigue at entry and after 1 year are shown in table 2. At entry 63% (65/ 
104) of the patients complained offatigue and 42% (44/104) of itching. 
After 1 year this was 49% (51/104) and 29% (30/104) respectively. This 
decrease was significant for both fatigue (p<0.03) and pruritus 
(p<O.OI). The percentage of symptomatic patients significantly 
decreased from 68% (71/104) to 51% (53/104) (p<O.Ol). 
Table 2. Presence of symptoms and abnortnal biochemical parameters 
at entry and 1 year. 
Symptoms 
Prtlyiflls 
Fatiglle 
Entry 
42% (44/104) 
63% (65/104) 
Biochemical parameters 
BiliYllbill 32% (33/104) 
AP/z 96% (100/104) 
AST 86% (89/104) 
IgM 93% (97/104) 
1 year P-value1 
29% (30/104) <0.03 
49% (51/104) <0.01 
26% (27/104) >0.1 
60% (62/104) <0.001 
42% (44/104) <0.001 
75% (78/104) <0.001 
P-vllue with respect to the di(ference between entry and I year of trcatment within each group 
(McNemar's test). 
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Biochemical remission 
After twelve months of treatment the mean levels of bilirubin 
(p=0.02),APh,AST and IgM (all p<0.001) were lower than at baseline 
(figure 1). The number and percentage of patients with abnormal 
biochemical parameters at entry and after one year is shown in table 2. 
After 12 months of treatment 29 patients had only 1 abnormal parame-
ter: IgM was still elevated in 19,APh was more than 1.5 times the 
upper normal value in 8 and AST was still above normal in 2 patients. 
1\velve of the 104 (12%) patients achieved a biochemical 
remission on UDCA. The majority of these patients had mild liver 
function abnormalities at entry and all had normal bilirubin levels. 
Characteristics at entry of these patients are given in table 3. 
At 12 months 10 of the twelve patients with a biochemical 
remission were without pruritus and 7 did not have fatigue at 12 
months. One patient had developed persistent £1tigue after 3 months of 
treatment, which seemed to be (at least partly) attributable to an inter-
current vital depression. Therefore 7/104 (7%) patients achieved a 
symptomatic and biochemical remission. 
Histological remission 
One patient died of cardiac arrest shortly after her 1-year visit; a 
liver biopsy was performed in the remaining 6 patients with a 
symptomatic and biochemical remission. One patient did not display 
any histological signs of active PEC and presented only aspecific 
reactive changes (slight portal and periportal fibrosis). In the other 5 
patients a predominantly Iymphocellular portal infiltrate was found. In 
3 of them the infiltrate affected the biliary epithelium, without 
evidence of actual bile duct destruction; in one of these 3 patients 
granulomas were found and in another patient granulomas and a 
periportal infiltrate with piecemeal necrosis. In the remaining 2 patients 
the biliary epithelium was not affected by the portal infiltrate; in one of 
them a periportal infiltrate with piecemeal necrosis was found. Thus the 
criteria for histological remission were fulfilled in 3 of the 6 biopsied 
patients. 
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Table 3. Characteristics at entry of patients attaining biochemical, 
sYlnptomatic and/or histological remission. 
Nr. Age Sex Histological Disease Bili APh AST IgM Pruritus Fatigue 
(yrs) (m/0 stage duration (x ULN) (yes/no) (yes/no) 
(yrs) 
Biochemical remission 
I. 56 f III <0.5 0.8 4.1 2.8 1.9 yes yes 
2. 73 f III 10 0.7 2.0 1.0 0.7 yes yes 
3. 51 f II <0.5 0.4 2.0 0.9 4.0 yes yes 
4. 71 f 15 0.8 2.2 0.9 1.3 no no 
5. 57 f II 0.3 4.1 0.9 0.6 no no 
Biochemical alld symptomatic remissiol1 
6. 56 f 5 0.2 1.8 0.6 1.4 no no 
7. 75 f II <0.5 0.5 1.7 1.1 1.4 no yes 
8.' 61 f 9 0.7 2.1 0.9 1.2 no no 
9. 53 f 8 0.5 1.8 0.7 1.5 no yes 
Biochemical, symptomatic alld histological rcm;sshlll 
10. 66 f 10 0.7 1.7 1.3 2.0 no yes 
11. 46 III IV <0.5 0.7 1.0 1.4 1.0 no yes 
12. 69 f <0.5 0.5 2.8 1.3 0.6 no no 
No liver biopsy within 1 year before entry available and 110 cirrhosis established in previotls biopsies. 
No liver biopsy after UDCA treatment available 
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Complete (biochemical, symptomatic atld lristological) remission 
Seven of the 110 initial patients (6%; 95% confidence interval: 2-
10%) achieved a biochemical and symptomatic remission and 3 patients 
also attained a histological remission. The patient in whom no biopsy 
could be performed might also have attained a histological remission; 
thus, the maximal number of patients attaining a complete remission 
according to our criteria was 4 (4%; 95% CI: 0-8%) (figure 2). 
year of treatment completed 
104 
Biochemical remission 
12 
Symptomatic remission 
7 
Histological remission 
(Complete remission) 
3 
Figure 2. 
All patients 
110 
No biochemical remission 
92 
No symptomatic remission 
5 
No histological remission 
3 
Treatment withdrawal 
6 
No liver biopsy obtained 
1 
Flowchart of the Ito patients entering the study, indicating the l1tuuber ofpaticllts stopping trcatment and 
of patients attaining biochemical-, dinical- (biochemical + symptomatic) and comple!1! (biochemical, 
symptomatic and histological) remissions. 
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DISCUSSION 
The results of this study confirm the already well-established 
effects ofUDCA on biochemical and immunological parameters of the 
disease in a homogeneous group of patients with non-advanced PBe. 
However, despite these marked overall improvements in laboratory 
parameters, an assessment of the effect ofUDCA on an individual basis 
shows that a biochemical, symptomatic and histological inactivation of 
the disease is rarely achieved. Our results further suggest that a 
remission may only occur in patients with mild disease activity. It is also 
clear that, although the number of symptomatic patients decreased, a 
large number of patients remains symptomatic on UDCA treatment. 
To define remission we used recently proprosed, strict criteria 
(19).These criteria are based on the definitions which have been 
extensively used in chronic autoimmune hepatitis (21). Since PBC is a 
cholestatic disorder with primarily involvement of the bile ducts, the 
criteria were slightly modified, especially with regard to alkaline 
phosphatase. To the best of our knowledge this is the first study in PBC 
in which the main outcome variable was remission of disease. This 
might be due to the absence of generally accepted criteria for 
remission. Obviously the validity of these criteria and the relation 
between clinical and histological remission must be flll'ther explored in 
future studies. 
With regard to establishing histological remission possible sample 
errors constitute a problem and may lead to underestimation of disease 
activity. Therefore, in our study the absence of clear histological activity 
in 3 of the liver biopsies after UDCA treatment can only be considered 
as suggestive for complete remission. 
We administered a dose of about 10 mg/kg UDCA in this study, 
in agreement with several other authors (10,14). It could be argued that 
a higher dose might lead to a higher remission frequency. However, this 
seems unlikely since the quantitative changes in Olll' study population 
are comparable with those reported in studies using higher doses 
(9,15,16). FlIl'thermore, the only dose response study with UDCA 
performed in chronic liver diseases indicated no extra benefit of a 750 
mg dose over a 500 mg dose dose (22). 
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It may not be surprising that UDCA monotherapy does not 
appear to be sufficient to induce disease inactivation in PBe. UDCA 
seems to interfere mainly with the consequences of cholestasis and not, 
or only to a minor extent, with the underlying inmlUnological disorder. 
Combined therapy of PBC with bile acids and other treatment 
modalities therefore seems a logical next step (23-28). 
In conclusion, our findings confirm that UDCA improves 
biochemical parameters and complaints in PBe. However, in spite of 
overall improvement, complete remission of disease activity in 
individual patients is rare. Therefore future studies should assess whether 
the use of additional treatment e.g. inmlunosuppressive drugs, will 
increase the number of patients in whom remissions can be achieved. 
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SUMMARY 
Objective: It has been suggested that patients with primary 
biliary cirrhosis (PBC) who have developed cirrhosis respond less to 
treatment with ursodeoxycholic acid (UDCA) than patients with non-
cirrhotic disease, and that UDCA may even induce clinical 
deterioration in these patients. Aim of this study was to compare the 
response to, and safety of UDCA treatment in PBC-patients with and 
without cirrhosis. 
Design and methods: Twenty cirrhotic patients with 
compensated (Child-Pugh Class A) PBC and 39 non-cirrhotic patients, 
were included in a Dutch, prospective, multicenter study. Symptoms 
(pruritus and fatigue) and biochemical parameters (Bilirubin,Alkaline 
Phosphatase [APh], AST, IgM and albumin) were assessed 3-monthly 
during 1 year of UDCA treatment (10 mg/kg/ day). Clinical 
deterioration was defined as de novo appearance of ascites or variceal 
bleeding, death or transplantation, doubling of bilirubin or a fall in 
albumin >6 gr/L. 
Results: The median percentage decreases from baseline of APh, 
AST and IgM were significant in both groups. No differences in res-
ponse were established between cirrhotic and non-cirrhotic patients for 
bilirubin (-9 vs. -10%),APh (-39 vs. -41%),AST (-38 vs. -45%), IgM 
(-25 vs. -20%) and albumin (+1 vs. 0%). The decrease from baseline in 
pruritus and fatigue did not significantly differ between groups. No 
major adverse effects were noted. Clinical deterioration was observed in 
one non-cirrhotic patient. 
Conclusions: The effects ofUDCA on symptoms and 
biochemical parameters of disease are comparable in PBC patients with 
non-cirrhotic and compensated cirrhotic disease. Moreover, in patients 
with compensated cirrhosis UDCA appears to be a safe therapy. 
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INTRODUCTION 
Primary biliary cirrhosis (PBC) is a usually slowly progressive 
autoimmune disease characterized by non-suppurative destructive 
cholangitis, cholestatic liver function abnormalities and the presence of 
antimitochondrial antibodies (1). 
Ursodeoxycholic acid (UDCA) is a hydrophilic, non-toxic bile 
acid which has become the drug of first choice for PBe. The mecha-
nism of action is thought to be based on the displacement of toxic 
endogenous bile acids from the liver cell, increased choleresis, hepato-
protective- and possibly immunomodulating properties (2-8). 
UDCA has documented beneficial effects on biochemical and 
immunological disease parameters and may ameliorate symptoms (9-
16). Also histological improvement has been reported (9,10). Although 
UDCA seems to slow down the rate of disease progression, a clear 
effect on histological progression, need ofliver transplantation and 
survival has not been consistently shown (17-19). Furthermore, UDCA 
rarely induces complete remission of the disease (20). 
Despite of its limited effects, the safety and virtual absence of 
adverse effects of UDCA have contributed to its current widespread 
use. However, it has been suggested that in patients in the cirrhotic 
stage of PBC, UDCA is not only ineffective, but may even indnce 
deterioration of the disease (21-25). Therefore a prospective study was 
initiated to compare the clinical and biochemical response to, and the 
safety ofUDCA in patients with and without cirrhosis. 
PATIENTS AND METHODS 
Sixty-four patients with PBC, diagnosed according to the criteria 
ofTaal et al. (26) and included in a 1-year, open prospective, 
multicenter study evaluating UDCA treatment were studied. Patients 
were excluded in the following cases: age >75 years, presence of 
another life expectancy limiting disease, evidence of extrahepatic bile 
duct disease on ultrasound, pregnancy or risk of pregnancy due to lack 
of suitable contraception and the use of UDCA within 3 months prior 
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to entry. Patients with advanced disease defined as Child-Pugh class B 
or C disease (27) were excluded as these patients were considered 
unlikely to benefit from medical therapy. Thirty-nine patients were 
classified as "non-cirrhotics" based on a liver biopsy obtained within 1 
year before start of the study and 20 as "cirrhotics", as previously 
established histologically. Liver biopsies were reviewed and classified 
according to Ludwig et al. (28) by one experienced pathologist (FJW t 
K.) who was not aware of the clinical state of the patients. The other 5 
patients were wrongly included as they already had Child class B 
cirrhosis. They were followed prospectively in a similar way, but were 
not included in the comparative study. 
Patients received UDCA (Ursochol® 300 mg tablets; Zambon 
B.V.,Amersfoort,The Netherlands) in a single late evening gift. The 
dose was adjusted according to body-weight: 450 mg if < 50 kg, 600 
mg if 50-70 kg and 750 mg if>70 kg (ca. 10 mg/kg/daily). 
A clinical examination was performed at entry and at 3-monthly 
intervals, including assessment of pruritus and fatigue and laboratory 
investigations (bilirubin, alkaline phosphatase (APh), alanine- and 
aspartate aminotransferases (AST, ALT), cholesterol, albumin, IgM, IgA 
and IgG). Furthermore prothrombin time and antithrombin-III activity 
were measured at entry. Pruritus and fatigue were assessed by semi-
quantative scores. Patients were asked to indicate the hours during 
which they had experienced pruritus and fatigue during the 7 days 
preceding each visit. The number of hours multiplied by the number of 
days resulted in a score ranging from 0-168 points. 
Hepatic deterioration was defined, using the (slightly modified) 
criteria of Mitchison et al. (29) as: liver transplantation or hepatic 
death, de ilOilO development of ascites or variceal bleeding, doubling of 
bilirubin, fall of albumin> 6 giL (at 2 consecutive measurements). 
Liver biopsies after 1 year of treatment were not demanded and were 
not performed in most patients. The criterium of progression to 
cirrhosis used by Mitchison was therefore not applied. 
Laboratory values are expressed as median percentage 
change from baseline or times the upper limit of normal (ULN). The 
absolute scores for pruritus and fatigue are given. Differences between 
values within the groups were analysed using the Wilcoxon's signed 
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Table 1. Patient characteristics at entry: cirrhosis vs. non-cirrhosis group 
(quant.tive data as medians+range [ .. ]). 
Cirrhosis Non-cirrhosis p= 
Nllmber 20 39 
Males 4 (20%) 5 (12%) 0.5 
Age (yrs) 60 [37-71] 54 [33-75] 0.07 
Disease dllratioll (yrs) 8 [0-17] 1 [0-19] 0.001 
Histological stage: 
I 13 
II 10 
III 16 
IV 20 
APh 4.0 [1.0-11.0] 3.1 [1.1-12.2] 0.1 
AST 2.5 [1.2-7.4] 1.6 [0.5-4.0] 0.09 
IgM 2.2 [1.0-16.8] 2.0 [0.6-10.6] 0.6 
Bilimbill 1.1 [0.5-4.6] 0.7 [0.1-2.8] 0.009 
Bilimbill > ULN 
(11= .. ) 11 (55%) 8 (13%) 0.007 
Bilimbill if> ULN 1.3 [1.1-4.6] 1.3 [1.1-2.8] 0.9 
Albllmill ill grlL 41 [29-48] 41 [20-48] 0.3 
APh,AST, IgM and Bilirubin given as multiples of the Upper Limit of Normal (ULN). 
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rank test and differences between groups using the Wilcoxon's ranksum 
test. Proportions were compared by the X"-test.A two-sided p-value 
sO.05 was considered significant. 
RESULTS 
Patient characteristics at entry are presented in table 1. In the 
cirrhotic patients, the duration of disease since diagnosis was longer and 
bilirubin levels were significantly higher. No other differences were 
noted. All patients had intact clotting as indicated by a normal 
prothrombin time. 
None of the studied patients withdrew from treatment and no 
major adverse effects were noted. Two patients reduced the UDCA 
dosage because of diarrhea: one cirrhotic patient (fium 750 to 300 mg) 
and one non-cirrhotic patient (600 to 300 mg). The diarrhea 
subsequently subsided and the patients maintained the lowered dose. 
The effect ofUDCA on pruritus and fatigue did not differ 
significantly between the cirrhotic and non-cirrhotic patient groups 
(pruritus p=0.5 and fatigue p=0.3). In view of the substantial number 
of asymptomatic patients the changes in only those patients who were 
symptomatic at entry and/or at 1 year are more illustrative (figure 1). In 
both the cirrhotic and non-cirrhotic patients decreases in pruritus score 
(median -13 and -15 points, respectively) and in fatigue scores (median 
-29 vs. -12 points respectively) were observed, which did not differ 
significantly between both groups (both p=0.6). 
In both cirrhotic and non-cirrhotic patients APh (-39% vs. -41% 
resp.),AST (-38 vs. -45% resp.) and IgM (-25 vs.-20% resp.) 
significantly decreased (all p<O.OOl); bilirubin (-9 vs. -10%; p=0.7 and 
p=0.07 resp.) and albumin (+1 vs. 0%; p=1 and 0.7 resp.) remained 
stable. No significant differences between both groups were found with 
respect to percentage change fium baseline after 1 year for any of the 
parameters (figure 2). 
None of the patients died, required a liver transplantation or 
developed ascites or variceal bleeding during this study. In the cirrhotic 
group 2 patients showed an increase in bilirubin. In one of them 
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thc difference between entry and 1 year within each group; the p-value below the figure applies to the 
ditlcrcllce in changes between both groups.All p-values and medians indicate the data for patients 
symptomatic at entry and/or at 1 year. The Iltllllber of patients who were asymptomatic at entry and at 
year are indicated below the graph, Two patients in the cirrhotic group (2 symptomatic of which one 
became asymptomatic) and two in the non-cirrhotic group (1 symptomatic at entry and during the whole 
follow lip period, one becoming symptomatic) were unable to fill in the pruritus score. Three patients in 
the cirrhotic group (2 symptomatic becoming asymptomatic and one asymptomatic becoming 
symptomatic) and four ill the non-cirrhotic group (all symptomatic at entry and during the whole follow 
up period) were unable to fill in the fatigue score. 
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signedbilirubin almost doubled (from 1.2 to 2.2 x ULN). However, this 
increase only started after 6 months ofUDCA. In the non-cirrhotic 
group 3 patients showed a minor increase of bilirubin (figure 3). One 
non-cirrhotic patient, in whom serum bilirubin remained stable, 
showed a decrease in albumin of 10 g/L.A liver biopsy was performed 
in this patient after 1 year ofUDCA which indicated progression from 
stage III to stage IV disease. 
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Percentage of baseline values of bilirubin, alkaline phosphatase,AST and IgM during one year of treatment 
with UDCA in patients with and without cirrhosis, expressed as medians with interquartiles. Percentage 
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Two of the 5 patients with Child Class B disease died within 1 
year from hepatic insufficiency; a third one showed disease progression 
and was transplanted 1 year after start of treatment. Two patients did not 
show disease progression and are still alive after respectively 1.5 and 2 
years offollow-up (table 2). 
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3 
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Figure 3. 
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Bilirubin levels (x Upper Limit of Normal) of patients with abnormal bilirubin levels at any time during 1 
year ofUDCA for those with cirrhosis (11=11) and without cirrhosis (n:o:l1), The horizontal lines represent 
the median levels for T""O and T= 1 year. The shaded <lfea represents the normal range. No significant 
differences were found bem'cen median leyels at entry. 6 months and 1 year. Patients with rising bilirubin 
levels are marked (e----e), 
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Table 2. Data of patients with initial Child B disease at entry (E), and at the end offollow-up (F). 
Patient Age Child-Pugh Bilirubin Albumin PT* Ascites Encepha- Outcome 
nr. In score at (fIDlollL) (gram/L) lopathy (duration until 
yr' entry outcome in yrs) 
E F E F E F E F E F 
1. 54 7 42 180 27 25 0 3 + LTx (1) 
2. 63 7 89 121 30 29 0 3 + + dead (1.5) 
3. 74 7 118 82 29 25 81% 3 + + dead (1) 
4. 61 7 43 79 26 28 0 1 -(d) alive (1.5) 
5. 62 7 34 32 31 30 45% 50% alive (2) 
*: PT ::::: Prothrombin Time as seconds above upper normal limit. When no Prothrombin Time available Antithrombin-III 
activity is given (normal> 80%) 
LTx Liver transplantation 
Cd) =: on diuretics for oedema 
DISCUSSION 
This study shows that PBC patients who have developed cirrhosis, 
but still have compensated disease, respond to UDCA treatment like 
patients without cirrhosis. Furthermore UDCA is well tolerated and 
does not induce deterioration of disease in such patients. The near 
doubling of bilirubin observed in one patient was unlikely to be related 
to the institution ofUDCA treatment as bilirubin started to increase 
after more than 6 months of treatment. 
It should be emphasized that only patients with compensated 
cirrhosis, defined as Child-Pugh class A disease, were included in the 
comparative study and that in only three of the twenty cirrhotic 
patients serum bilirubin was elevated more than twice the upper limit 
of normal at entry. Our results are in agreement with the findings of 
Battezzatti et al. (14) who performed a randomized controlled trial in 
88 patients with either pruritus (90 %) or a serum bilirubin exceeding 2 
mg/dL (33 %). Histological cirrhosis was present in 50 % of the pa-
tients. UDCA significantly improved liver biochemistry, including 
serum bilirubin in patients with elevated levels at entry. These and our 
results seem to be in conflict with other reports (12,16,25). Floreani et 
al. (25) recently reported absence of an effect ofUDCA on liver bio-
chemical tests in 11 patients with stage IV disease. In 3 patients serum 
bilirubin was above 2 mg/ dL. Hadziyannis reported biochemical 
improvements in 13 cirrhotic patients, though less pronounced than in 
non-cirrhotic patients (16). Preliminary data from a controlled study by 
Combes et al. in 153 patients suggest that the majority of patients with 
bilirubin C 2 mg/dL is unlikely to benefit from UDCA (12).At present 
there seems to be no obvious explanation for these contrasting results. 
In these studies individual data on serum bilirubin and Child-Pugh 
score were not reported and it could be speculated that inclusion of 
cirrhotic patients with more advanced or decompensated disease ac-
counts for the different results. 
Longer follow-up of small numbers of patients with late stage 
disease has indicated that, after 2-5 years, initial improvements may 
worsen again and that disease complications occur more often in these 
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patients than in early stage patients (16,25,30). Our study has a 
relatively short follow-up but we do not doubt that further follow-up 
will show the same pattern, considering the minor effect of UDCA on 
the natural course of the disease. Naturally, signs of progression will first 
become evident in patients with cirrhosis. Though it could be argued 
that these signs would have occurred earlier and more frequently wit-
hout the use ofUDCA, this can only be proved by controlled studies in 
cirrhotic patients. 
Is UDCA safe for PBC patients with cirrhosis? Our results 
indicate that UDCA is well tolerated and safe for patients with 
compensated disease. Most studies on UDCA treatment included 
patients with cirrhosis, and in several large series no patients were 
reported with deterioration due to UDCA (14-20). Nevertheless, 
occasional patients have been reported with deteriorating disease after 
introduction ofUDCA with amelioration after discontinuation or dose 
reduction in some cases (21-23). Kneppelhout et a!. (22) retrospectively 
studied 13 patients with stage III and stage IV PBC who were treated 
with UDCA. The majority (10/13) of these improved both clinically 
and biochemically. However, in three of the nine patients with stage IV 
disease bilirubin increased markedly. One patient showed progression 
despite discontinuation ofUDCA and was eventually transplanted, one 
patient improved after dose reduction and one after interruption of 
UDCA. In these three patients initial serum bilirubin levels varied from 
32-56 Ilmol!L (normal up to 17 Ilmol!L) and was highest in the 
patient requiring liver grafting. Moreover the four patients who 
deteriorated on UDCA, reported by Hwang et a!. and Vogel et a!. had 
initial bilirubin levels varying from 1.5-4.4 times the upper limit and 
were elevated more than twice in three of them (21,23). Further details 
regarding the course of the disease and hepatic function before 
treatment were not provided clearly. Therefore the observed 
deterioration in these reports may have represented the natural course 
in patients with already decompensating disease. Our results suggest 
that in patients with Child-Pugh class B no clinically significant 
beneficial effect ofUDCA can be expected and progression of the 
disease may even be accelerated. However, differentation between 
58 
natural progression of disease and deterioration due to bile acid treat-
ment remains difficult. 
We would like to suggest the following policy: patients with 
Child-Pugh class A, and serum bilirubin levels less than twice the upper 
limit of normal can be expected to respond to UDCA like non-
cirrhotic patients. Special precautions when initiating treatment with 
UDCA are not necessary. 
Patients with compensated Child-Pugh A cirrhosis and bilirubin 
levels above 2 times the upper limit of normal may be at risk for res-
ponding adversely to UDCA. These patients should start UDCA with 
about 5-6 mg/kg/ day, and be reinvestigated with performance ofliver 
biochemical tests after 2, 4 and 8 weeks. In the absence of problems the 
dose I11ay thereafter be increased to 10-15 mg/kg/day, with further 
check-ups after 4 weeks and increasing intervals thereafter. 
Patients with cirrhosis and evidence of decompensating or 
severely advanced disease, defined as presence of Child-Pugh class B or 
C disease, are very unlikely to benefit from any medical treatment, 
including UDCA. In these patients liver transplantation should be the 
primary therapeutic consideration. 
In conclusion, PBC patients with compensated cirrhosis can be 
expected to respond clinically and biochemically in the same way as 
patients without cirrhosis, and UDCA is very well tolerated by such 
patients. Only subgroup analyses of patients participating in large, long 
term controlled trials may prove whether UDCA is associated with a 
beneficial effect on the course of the disease in cirrhotic patients. 
However, until such information becomes available, we believe that 
patients with histological cirrhosis should not be routinely denied 
treatment with UDCA. 
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SUMMARY 
Background: UrsodeoA],cholic acid (UDCA) improves liver 
biochemistry in primary biliary cirrhosis (PBC) and primary sclerosing 
cholangitis (PSC). Since UDCA acts partly by reducing the intestinal 
absorption of hydrophobic endogenous bile salts (BS) and is poorly 
absorbed from the intestine, a multiple dose regimen has been advo-
cated. Single dose treatment on the other hand may improve complian-
ce. The effects of a single or multiple dose regimen on liver enzymes 
and serum and biliary BS composition were evaluated. 
Methods: 27 patients (19 PSC, 8 PBC) received during 3 months 
UDCA (10 mgkg- I day-') in a single dose at bedtime (n=13) or in 3 
divided gifts with meals (n=14). 
Results: Liver biochemistry equally improved in both groups. 
Biliary enrichment (% UDCA of total BS, mean±SEM) was 38.2±2.5 
in the single dose group vs 35.5±2.5 in the multiple dose group 
(p=NS) and positively correlated with biochemical improvement (AP: 
r=0.47,p=O.02; y GT: r=O.58,p=O.002;ASAT: r=O.67,p=O.002; 
ALAT: r=O.52,p=O.Ol). Biochemical improvement did not correlate 
with the concentration or % UDCA in serum. 
Conclusions: Single and multiple dose UDCA have equal effects 
on liver biochemistry and biliary enrichment in cholestatic liver disease. 
Biochemical improvement is related to biliary (but not serum) 
enrichment with UDCA. Single dose treatment is more convenient, 
may improve compliance, and is therefore preferable to a multiple dose 
regimen 
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INTRODUCTION 
The bile salt ursodeO},),cholic acid (UDCA) is currently 
considered the standard therapy for cholestatic liver diseases such as 
primary biliary cirrhosis (PBC) and primary sclerosing cholangitis 
(PSC)(1-6). UDCA is a hydrophilic bile salt and probably protects the 
hepatocyte directly against the toxicity of accumulated hydrophobic 
endogenous bile salts such as chenodeoA),cholic acid (CDCA) and 
deoA),cholic acid (DCA) (7). Other suggested mechanisms of action are 
an iml11unomodulatory effect (8,9), the induction of hyper choleresis 
(10-12) and competitive inhibition of intestinal absorption of toxic 
endogenous bile salts (13-15). UDCA is a poor micel former and is 
poorly solubilized in the intestinal lumen (16,17). Consequently, the 
absorption rate ofUDCA is low as compared to other bile salts (18-
20).The active transport of conjugated bile salts in the ileum is limited 
to a maximum. Although higher doses ofUDCA lead to higher biliary 
enrichment, the proportion of UDCA absorbed decreases with higher 
doses (19,20). Furthermore, since bile is mainly secreted during meals, 
and UDCA is supposed to inhibit the absorption of endogenons bile 
salts, it seems more appropriate to administer UDCA with meals. 
Therefore, a multiple dose rather than a single dose treatment with 
UDCA, has been advocated for cholestatic liver disease (20). Indeed, 
preliminary data from the group of Stiehl suggested a higher absorption 
ofUDCA during multiple dose treatment than during single dose 
treatment in 4 patients with biliary obstruction and external biliary 
drainage (mean±SEM: 58.7±1O.9% vs 44.4±11.2%) (21). On the other 
hand, a single dose regimen is more comfortable for the patient and 
will improve treatment compliance. Moreover, a single dose 
administration at bedtime appeared to be more efficacious than meal 
time administration for cholesterol gallstone dissolution (22) .Whether 
there is any difference in efficacy between multiple or single dose 
treatment with UDCA for cholestatic liver diseases has never been 
studied. We therefore decided to study the improvement of liver 
enzymes and the bioavailablity of UDCA, as reflected in serum and 
biliary enrichment, during a single dose and a multiple dose regimen in 
patients with PSC and PBe. 
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MATERIALS AND METHODS 
Protocol 
Nineteen PSC and 8 PBC patients were randomly assigned to a 
group receiving UDCA 10 mgkg-'day-' (Ursofalk, Falk GMBH, 
Freiburg Germany) in a single dose, taken with a small snack at bed-
time (n=13), or in 3 divided doses with meals (n=14) during 3 months. 
Both groups (single vs multiple dose) were comparable for age 
(mean±SD: 40±7 vs 45±15), sex (M/F: 914 vs 8/6), disease (PSCI 
PBC: 9/4 vs 10/4) and disease stage (early stage I late stage disease: 101 
3 vs 1212). Early stage disease was defined as stage I-II, late stage disease 
as stage III-IV, as described by Ludwig for PBC (23) and PSC (24). 
Liver biochemistry was comparable between groups (table 1). In each 
patient at least one of the standard liver tests (bilirubin,Alkaline 
Phosphatase [AP), yGT,ASAT,ALAT) was elevated more than 1.5 
times the upper limit of normal. 
Table 1. Effect of single or mUltiple dose UDCA (10 mgkg-'day-') on 
liver ellzytnes (mean ± SEM). 
Single dose (n= 13) Multiple dose (n= 14) 
before UDCA during UDCA before UDCA during UDCA 
Bilirubin 
(~mol!L) 16.5 ± 1.8 14.2 ± l.l 16.4 ± 2.4 12.6 ± 1.9* 
AP (u/L) 383.8 ± 63.9 227.3 ± 31.9t 357.4 ± 60.3 203.0 ± 36.9t 
yGT (u/L) 448.2 ± 118.6 197.6 ± 56.9t 455.1 ± 78.3 157.5 ± 29.7t 
ASAT (u/L) 71.7 ± 17.2 31.3 ± 4.4* 60.7 ± 9.2 32.4 ± 5.4t 
ALAT (u/L) 109.1 ± 27.1 42.0 ± 8.2t 88.6 ± 12.6 43.4 ± 6.9t 
* p < 0.05 versus pretreatment value, no difference between groups. 
t p < 0.01 versus pretreatment value, no difference between groups. 
Normal ranges: Bilirubin: <17 ~mol/l;AP: 27-93 U/1; yGT: (male) 8-46 U/1, 
(female) 7-29 U/1;ASAT: <30 U/1;ALAT: <30 U/i. 
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All patients were classified as class A according to the Child-Pugh 
classification. Anti-mitochondrial antibodies were positive in all PBC 
patients and in none of the PSC patients. In all patients liverbiopsy was 
compatible with the diagnosis; all PSC patients had an ERCP 
confirming the diagnosis. Eleven (58%) PSC patients had concomitant 
inflammatory bowel disease, however, none of them had active disease 
during the study. Colectomized patients and patients treated with bile 
salt sequestrants (e.g. cholestyramine) were excluded from the study.All 
other medication was continued at a fixed dose throughout the study. 
Five patients (1 PSC and 4 PBC, 3 early stage and 2 late stage 
disease) consented to have an additional treatment of 3 months 
according to a cross-over design, with a 1 month wash-out period in 
between (initial treatment: single dose in 2, multiple dose in 3). In all 
patients, laboratory findings returned to pre-treatment values during 
the wash-out period. 
The protocol was approved by the ethical committee of our 
hospital and all patients gave informed consent. 
Bile salllplitlg 
Bile samples were collected in fasting patients at 9.00 am. before 
and after 3 months ofUDCA. In the cross-over part bile samples were 
also taken after 7 months, at the end of the second treatment phase. 
Patients had their last medication the previous day with dinner (multi-
ple dose) or at 10.00 pm. with a small snack (single dose).A catheter 
was positioned under fluoroscopic control in the descending part of the 
duodenum and the gallbladder was stimulated with an intravenous 
bolus injection of ceruletide (0.3 Ilg/kg).Aspirated bile was collected in 
ice-chilled tubes. Three milliliters of the most concentrated bile was 
directly transferred to the laboratory for further analysis. The remaining 
bile was returned through the catheter to avoid bile salt depletion. 
Bile analysis 
Total bile salt concentration was measured in whole bile using 
3a-hydrO>.:ysteroid dehydrogenase according to Turley (25). Conjugated 
bile salt species were analyzed in whole bile by isocratic high 
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performance liquid chromatography on a \lV':1ters Bondapak C-18 10 /.U11 
column (using methanol! phosphate buffer as solvent, pH 5.2, flow rate 
1 ml/min) and detection at 200 nm (26). Cumulative hydrophobicity 
indices were calculated for bile salt species according to Heuman (27). 
Blood samplillg atld allalysis of seYllm bile salts 
Blood samples were taken for determination ofbilirubin,Ap, 
y GT, ASAT, ALAT and serum bile salts. Serum bile salts were 
determined before and during UDCA in the first 16 consecutive 
patients studied (single dose n=7; multiple dose n=9). Of these, 13 had 
early stage disease and 3 (all single dose) late stage disease. Serum bile 
salt concentrations were measured by capillary gas-liquid 
chromatography as described previously (28). 7a,12a-dihydroxy-5B 
cholanoic acid was added as an internal standard. Bile salts were 
extracted from serum using Cl8-bounded silica cartridges (SepPak, 
Waters Associates, Milford, MA, USA) (29). Separation of conjugated 
and uncoqjugated bile salts was carried out by means of column 
chromatography using the lipophilic anion exchanger 
diethylaminohydrm.:ypropyl Sephadex LH-20 (Lipidex-DEAp, Packard 
Instruments, Groningen, The Netherlands) (29). The conjugated 
fractions were subjected to enzymatic hydrolysis by cholylglycine 
hydrolase (from Clostridium perfringens).After enzymatic hydrolysis, 
the deconjugated bile salts were extracted and eluted on Lipidex-1000 
columns (Packard Instruments, Groningen, The Netherlands). The bile 
salts were converted to methyl esters by 2,2-dimethoxypropane. After 
methylation, trimethylsilyl ether derivates were prepared by addition of 
a solution of pyridine, hexamethyldisilazane and trimethylchlorosilane 
(3:2:1 by voL). Separation and quantification of bile salts was performed 
on a Packard 430 gas-liquid chromatograph with a flame ionisation 
detector and eqnipped with a 25 m x 0.25 mm glass capillary column 
(CP-Sil-5 CB, Chrompack, Middelburg, The Netherlands). 
Data allalysis 
Results are expressed as means ± SEM. Data were analysed using 
paired and unpaired (-tests for normally distributed data, Wilcoxon rank 
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sum and signed rank tests for non-parametric data. Correlations were 
determined with linear regression analysis between biochemical res-
ponse (% decreaselincrease from baseline), serum concentrations of 
UDCA and % UDCA of total bile salts in bile and serum. Patients with 
normal pre-treatment liver enzymes were only taken into account for 
regression analysis when a rise above the upper limit of normal was 
observed during UDCA treatment. From the 5 patients who 
participated in the cross-over design only the results of the first 
treatment phase were used for regression analysis (single dose in 2 and 
multiple dose in 3). A two-tailed probability of p '" 0.05 was considered 
significant. 
RESULTS 
Biochemical respo/lSe 
Treatment with UDCA resulted in a significant decrease of AP, 
y GT, ASAT and ALAT both in patients treated with a single dose and 
multiple dose. Bilirubin also decreased, however significance was 
reached in the multiple dose group only (table 1). The improvement of 
liver enzymes, including bilirubin, did not differ significantly between 
the two groups. 
Biliary bile salts 
Pre-treatment biliary bile salt composition was comparable in 
both treatment groups and was modified in a similar way during 
UDCA (table 2). Cholic acid (CA) was the major biliary bile salt before 
therapy followed by CDCA. During treatment, in both groups UDCA 
became the major bile salt with a significant decrease of the proportions 
of CA and CDCA. Accordingly, the hydrophobicity index decreased 
from 0.23±0.02 to -0.01±O.02 in the single dose group and from 
O.24±O.02 to O.03±O.02 in the multiple dose group (p<O.OOl in both 
groups, difference between groups non significant). 
Regression analysis showed a positive correlation between 
biochemical response and biliary enrichment with UDCA in patients 
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Table 2. Effect of single or multiple doses of UDCA (10 mgkg"day") 
on biliary bile salt species' (% of total ±SEM) in choIestatic 
liver disease. 
Single dose (n=13) Multiple dose (n=14) 
before UDCA during UDCA before UDCA during UDCA 
TCA 20.9 ± 4.1 9.7 ± 1.81 22.7 ± 4.1 9.4 ± 1.41 
GCA 36.2 ± 3.0 25.2 ± 1.91 32.4 ± 2.3 24.6 ± 1.81 
CA (T+G) 57.2 ± 3.2 34.9 ± 3.3' 55.1 ± 4.0 34.0 ± 2.6' 
TCDCA 10.8 ± 1.6 5.3 ± 0.7' 11.7 ± 1.6 5.4 ± 0.6' 
GCDCA 21.5 ± 2.2 15.5 ± 1.01 22.6 ± 3.1 17.6 ± 1.1 
CDCA (T+G) 32.3 ± 1.1 20.8 ± 1.0' 34.3 ± 2.7 22.9 ± 0.8' 
TDCA 1.6 ± 0.5 1.0 ± 0.2 1.8 ± 0.6 1.2 ± 0.3 
GDCA 6.4 ± 2.0 4.5 ± 1.2 6.9 ± 2.3 6.1 ± 1.8 
DCA (T+G) 8.0 ± 2.4 5.6 ± 1.4 8.7±2.7 7.2 ± 2.0 
TUDCA 0.6 ± 0.2 4.6 ± 0.5' 0.4±0.1 4.6 ± 0.7' 
GUDCA 0.9 ± 0.2 33.6 ± 2.4' 1.1 ± 0.4 30.9 ± 2.3' 
UDCA (T+G) 1.5 ± 0.2 38.2 ± 2.5' 1.5 ± 0.4 35.5 ± 2.5' 
Hydrophobicity 0.23 ± 0.02 - 0.01 ± 0.02' 0.24 ± 0.02 0.03 ± 0.02' 
Index ¥ 
* T.1urine (T) and glycine (G) conjugated biliary bile salts have been determined 
with HPLC. LeA accounted for less than 1% of total bile salts both before and 
during therapy. CA=cholic acid; CDCA=chenodeoxycholic acid; 
DCA=deoxycholic acid; UDCA=ursodeoxycholic acid. 
t p < 0.0 1 versus pre-treatment value, no difierence between groups 
+ p < 0.001 versus pre-treatment value, no difference between groups 
¥ Hydrophobicity Index calculated according to Heuman (27) 
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with pre-treatment elevated liver enzymes (figure 1). Normal liver 
enzyme values at entry did not exceed the upper limit of normal 
during treatment, except in 1 patient participating in the cross-over 
study, who showed a small rise of AP during multiple dose UDCA. 
Biliary enrichment with UDCA (% of total bile salts ± SEM) was 
not different in patients with early stage disease (37.0±1.9%) or late 
stage disease (37.9±2.8%) and patients with PSC (37.1±1.9) or PBC 
(39.2±3.7) . 
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Figure 1. 
Improvement of liver enzymes (% aCpee-treatment) in relation to biliary enrichment with UDCA (% of 
total bile salts) as determined with linear regression analysis in patiellts with pre-treatment elevated liver 
enzYllles, treated with a multiple dose (.) Of single dose (0) regimen ofUDCA (10 mgkg"'day'), Patients 
with normal pre-treatment liver biochemistry (0) are shown on the site on the X-axis corresponding to 
their level of biliary enrichmellt.ln none of these patients, enzymes exceeded the upper limit of normal 
during treatment. 
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Sertlfll bile salts 
The pre-treatment concentrations of fasting total serum bile salts 
(sum of conjugated and unconjugated fractions) were much higher than 
previously described by our group in healthy subjects (n=22, range: 
1.4 - 10.7 f.(l1101l1) (28,29).Total serum bile salts increased from 
31.9±13.1 to 56.6±19.8 pmolll during treatment, due to a strong 
increase ofUDCA (0.2±0.1 vs 35.6±13.1 pm01l1,p<0.05). UDCA 
therapy resulted in a significant decrease of % CA and CDCA and a 
significant increase of% UDCA. These changes were very similar in 
single and multiple dose groups (table 3). Conjugated UDCA 
accounted for 92.8% of total UDCA in serum. 
A positive correlation was found between % UDCA in serum and 
bile (r=0.55, p=0.03).The improvement of liver biochemistry did not 
correlate with % UDCA (0.03<r<0.31 and 0.30<p<0.92) or 
concentration UDCA (-0.02<r<0.29 and 0.28<p<0.97) in serum. 
Cross-over stlldy 
Biochemical response and biliary bile salt composition were 
comparable during both treatment regimens in 5 patients who 
participated in the cross-over study (figure 2). 
Table 3. Effect of single or multiple doses of UDCA (10 mgkg"day") on 
serUln bile salts· (% of total ± SEM) in cholestatic liver disease. 
Single dose (n=7) Multiple dose (n=9) 
before UDCA during UDCA before UDCA during UDCA 
CA 41.6 ± 2.3 14.7 ± 1.7/ 43.0±2.7 19.0±1.91 
COCA 48.8 ± 3.9 16.8 ± l.4t 45.8 ± 3.1 19.3± 1.7t 
DCA 8.4 ± 4.1 4.7 ± 1.7 8.9 ± 3.3 4.1 ± 0.8 
UDCA 1.2 ± 0.6 63.8 ± 2.31 2.3 ± 0.9 57.6 ± 3.1t 
* Bile salt concentrations (sum of conjugated and unconjugated) have been 
determined with gas-liquid chromatography. 
t p < 0.05 versus pre-treatment value, no difference between groups. 
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Figure 2. 
Changes in liver enzymes CUlL) and bilirubin (Jll1loI/1) (upper panel) and percentages of biliary bile salts 
(lower panel) in 5 patients treated in cross-over design with UDCA (to mgkg-1day-l) at base-line Qeft bars, 
• ), during single dose (middle bars, 0) and multiple dose (right bars, 0). * p<O.05; # p<O.OOl. 
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DISCUSSION 
Our results show that after three months ofUDCA at a dose of 
10 mgkg-1day-l, both biochemical improvement and biliary enrichment 
are equal during a single and a multiple dose regimen in patients with 
cholestatic liver disease. Our findings are in contrast with previous 
studies that have shown a poor intestinal absorption of UDCA 
particularly when given in a single dose (20,21). However, in these 
studies the recovery ofUDCA in bile was evaluated after a single bolus 
administration of UDCA. Our results indicate that during chronic 
treatment with UDCA the mode of administration is neither a 
determining L1ctor for biliary enrichment, nor for biochemical res-
ponse. A possible explanation for this finding is the fact that UDCA, 
once absorbed, will recirculate mainly as conjugated UDCA in the 
enterohepatic circulation. This is supported by the finding that in our' 
population 92.8% of serum UDCA was conjugated. It can be 
hypothesized that during chronic treatment most of the UDCA 
absorbed in the ileum is derived fi'om the circulating pool of 
conjugated UDCA. 
In cholestatic liver disease, not only the intestinal uptake but also 
the handling ofUDCA by the liver is important for biliary enrichment 
(30). Failure of the liver to excrete the amount ofUDCA absorbed 
fi'om the ileum will be reflected by high concentrations ofUDCA in 
serum (31).The finding of high serum bile salt concentrations in our 
patients underlines the hypothesis that the excretion of UDCA by the 
liver is the limiting factor for biliary enrichment in cholestatic liver 
disease (30,32). Consequently, we believe that the mode of 
administration of UDCA as a single or a mnltiple dose regimen is 
irrelevant. 
Biochemical improvement positively correlated with biliary 
enrichment with UDCA as has been fonnd by others (33-35). On the 
other hand, no relation was found between biochemical improvement 
and concentration or % UDCA in serum. These findings snggest that 
the hepatoprotective properties ofUDCA take place at the level of the 
canalicular membrane rather than the basolateral membrane. This is in 
line with recent findings of Heuman et al. (36). They showed in vitro 
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that the membrane stabilizing property ofUDCA requires a relatively 
high (2::0.5) cholesterol I phospholipid (C/P) ratio of the membrane. 
Since the canalicular membrane has a nlUch higher C/P ratio than the 
basolateral membrane, they hypothesize that UDCAacts at the 
canalicular membrane rather than the basolateral membrane. This 
theory is supported by the fact that UDCA appears to be 
hepatoprotective in rats with bile salt induced cholestasis (37,38) but 
not, or to a lesser extent, in rats with completely blocked bile secretion 
due to bile duct ligation (39,40). These findings are in contrast with 
recent data from Giildiituna et al. suggesting that UDCA, like choleste-
rol, stabilises the basolateral rather than the canalicular membrane (41). 
The positive correlation between biliary enrichment with UDCA 
and biochemical response should be regarded with.dution. 
Theoretically, good biochemical response and high biliary enrichment 
with UDCA may both be secondary to improved liver function. Indi-
rect evidence has been provided that UDCA improves the excretory 
function of the liver.Jazrawi et al. have shown an improved hepatic 
excretory rate and transit time of 75SeHCAT during treatment with 
UDCA in patients with cholestatic liver disease (30). Colombo et aI., 
using hepatobiliary scintigraphy, demonstrated improvement of liver 
excretion in patients with cystic fibrosis and cholestatic liver disease 
(42). Further studies are needed to find out whether biliary 
enrichment, often used as a parameter in dose response studies, is 
indeed a prerequisite for biochemical improvement. 
In conclusion, this study shows that single bedtime administration 
and multiple (3 times a day) mealtime administration ofUDCA have an 
equal beneficial effect on liver enzymes and lead to similar biliary 
enrichment with UDCA in patients with cholestatic liver disease. 
Biochemical improvement is related to the proportion ofUDCA in 
bile but not in serum. In our opinion a single dose treatment is more 
convenient to the patient, may improve compliance and is therefore to 
be preferred to a multiple dose regimen. 
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SUMMARY 
Objective: To assess the effect of combined therapy (CT) of 
ursodem.:ycholic acid (UDCA) with prednisone on symptoms and 
biochemistry in patients with non-advanced Primary Biliary Cirrhosis 
(PBC), who had responded insufficiently to either drug alone. 
Methods: Retrospective evaluation of the eRect of 1 year of CT 
on symptoms (pruritus, fatigue, arthralgia) and biochemical parameters 
(bilirubin, alkaline phosphatase (APh) , Aspartate Aminotransferase 
(AST) and IgM) in 7 symptomatic patients. 
Results: Five of the seven patients became asymptomatic. Pruritus 
disappeared in 2 of 3 patients, L1tigue in 4 of 6 and arthralgia in 
both symptomatic patients. APh and AST decreased in all patients 
(median 41% and 59%, respectively). IgM decreased, although to a 
lesser degree (median 16%),in all but one patient. Normal levels for 
AST were achieved in 4 patients. In 2 of these APh normalized too. In 
2 patients IgM became normal. Bilirubin, only slightly elevated in one 
patient, remained stable in all. The beneficial effects were maintained 
during follow-up (median 1.5 years). The treatment was well-tolerated 
by all patients. 
Conclusions: In PBC, combined treatment with UDCA and 
prednisone appears to improve symptoms and biochemical parameters 
to a larger extent than either treatment alone; randomized controlled 
trials should be performed to establish the benefit/risk ratio of this 
combination therapy. 
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INTRODUCTION 
Primary Biliary Cirrhosis (PBC) is a chronic, usually slowly 
progressive cholestatic liver disease of unknown cause (1). Efforts to 
establish medical therapy that prevents patients to progress to liver 
£~ilure and improve prognosis have been largely unsuccessful (2). Such 
therapy should ideally be aimed at eliminating the cause of the disease, 
which, however, is still not elucidated. Therefore no causal, but only 
symptomatic and supportive therapy is feasible at the moment. In PBC 
both auto-immune mechanisms and liver damage caused by alterations 
in bile acid metabolism seem of m~or pathogenetic importance and 
consequently most therapeutic studies have focused on modulation of 
these factors (3). 
In general the results obtained with immunosuppressives have 
been disappointing (4-10). In contrast to chronic auto-inmlUne hepati-
tis no agent has been shown to be capable to induce complete inacti-
vation of the disease (11). The significant adverse effects of several drugs 
(e.g. cyclosporine, chlorambucil) further limit the clinical usefulness of 
immunosuppressive treatment. Recently promising results with methot-
rexate in PEC have been reported, but data from controlled trials have 
to be awaited (12). 
Prednisolone has been evaluated in one controlled trial. The 
results were encouraging and especially the absence of a clear adverse 
effect on bone mineral density was reassuring (13). 
Ursodeo>,'ycholic acid (UDCA) has been reported to exert a 
beneficial effect on symptoms, liver biochemistry and histology, and 
adverse effects are virtually absent (14,15). Many therefore consider 
UDCA the first treatment option for PEe. However, progression of the 
disease has been observed during UDCA treatment and the potential to 
stop histological progression or improve survival is still unclear (16). 
Preliminary reports of up to 4 years of follow-up did not show any 
improvement in survival (17-19), though in one study significantly less 
liver transplants were pet{ormed (19). 
The limited benefit of any single drug regimen in PEC, has 
stimulated investigators to propagate and explore the combination of 
bile acid treatment with other drugs (20-23). In one trial, adding 
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colchicine to UDCA did not seem to improve the results obtained with 
UDCA alone (22).Additive beneficial effects ofUDCA and metho-
trexate, in reducing bilirubin and alkaline phosphatase serum levels 
were recently described, although methotrexate led to increased ALT 
levels (23). 
We here report our experience with combining bile acid and 
corticosteroid treatment in patients who had no satisfactory response to 
either regimen alone. 
MATERIALS AND METHODS 
In december 1992 we reviewed the records of the 75 PBC patients 
under surveillance at our clinic. Seven patients with clinically non-
advanced disease were found, who were simultaneously treated with 
UDCA and prednisone. In all the diagnosis ofPBC was based on the 
presence of cholestatic liver function abnormalities (alkaline phospha-
tase more than 2x the upper limit of normal), an elevated serum IgM, 
anti mitochondrial antibodies (determined by conventional 
immunoflueorescence techniques using rat kidney tissue) and histologic 
features of PBe. None of the patients had sufTered from complications 
such as ascites, variceal bleeding or encephalopathy. All were in class A 
according to the Child-Pugh classification. All patients had a complete 
follow-up until! this evaluation (median 1.5 years, range 1-4). The main 
patient characteristics and treatment data are shown in table 1. 
Our center is a tertiary referral center for liver diseases. All but 
one patient were referred to us without prior treatment, after the 
diagnosis of PBC was made, because of the known interest and exper-
tise in our clinic with respect to this disease. One patient (patient 5) 
had been tought to suffer fi·om Chronic Autoimmune Hepatitis, and 
was referred to our center because she was only partially responding to 
inmlllnosuppressive therapy. In our clinic the diagnosis ofPBC was 
established. 
The moment at which combined therapy was instituted, i.e. the 
moment one drug was added to the other, was considered the 
inception point for this study. Two patients started UDCA with later 
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addition of prednisone. The latter was started 6 months after initiating 
UDCA. This 6-month period may allow the conclusion that clinical 
changes occurring after initiating combined therapy (CT) are 
attributable to the prednisone addition because UDCA exerts its maxi-
mum effect within the first 3 months (14, own experience). The other 
five patients had been on long term prednisone treatment before 
UDCA was started (median 7 years; range 5-14). In each of the 5 
patients who were on prednisone previous attempts to withdraw this 
drug had resulted in clear symptomatic and biochemical deterioration. 
Three of these patients were also on azathioprine 50 mg daily for at 
least two years. The main reason to institute additional treatment, 
UDCA or prednisone, was the persistance of symptoms. 
The main complaints in these patients, i.e. pruritus, fatigue and 
arthralgia were scored as either being present or absent before and after 
6 and 12 months of CT. Three monthly laboratory evaluations included 
Table 1. Data on demography, histology and drug administration at the 
start of cOlnbined therapy. Patients 1 and 2 were first treated with 
UDCA alone. Patients 3-7 were on corticosteroid therapy before 
UDCA was added. 
Patient Sex Age Histologic Duration Pred*/ Aza UDCA Follow-up 
nr. stage imm.sllp. dose dose onCT 
(years) (mg/ day) (mg/kg/ day) (months) 
1. F 41 II 15/- 8.6 48 
2. F 68 II 10/- 8.6 48 
3. F 49 II 7 10/50 8.8 24 
4. M 70 III 6 10/50 7.5 12 
5. F 67 IV 14 5/50 9.2 18 
6. F 60 II 5 7.5/- 7.5 18 
7. F 67 IV 11 12.5/- 9.2 15 
Median: - 67 7 10 8.6 18 
* Maintenance doses. 
83 
measurement of serum bilirubin, alkaline phosphatase (APh), aspartate 
aminotransferase (AST) and IgM.The mean of2 values obtained within 
3 months before CT were considered as baseline level. 
Considering the number of patients no statistical analyses were 
performed. This study was pet{ormed in adherence with the 
guidelines of Sackett et al. for studies on clinical course and prognosis 
(24). 
RESULTS 
Table 2 provides information on the presence of symptoms in 
relation to treatment. During the combined prednisone-UDCA 
therapy five patients became asymptomatic. In two of the three patients 
with itching and four of the six patients with fatigue these symptoms 
disappeared. In both patients with complaints of arthralgia the pain 
disappeared. In two patients symptoms were not relieved. 
In table 3 the absolute values as well as the decreases of baseline 
(in percentages), of APh,AST and IgM on 6 and 12 months of CT are 
presented.APh and AST decreased in all patients (median after 12 
months 41 and 59%, respectively). IgM decreased, although to a minor 
degree (median after 12 months 16%), in all but one patient. The 
largest effects on IgM were observed in the two patients in whom 
prednisone was added to UDCA. The main decreases occurred in the 
first 3-6 months of treatment. 
Bilirubin levels were normal in all but one patient (median 9, 
range 9-21). Patient 4 had an increased level of21 flmollL at entry 
(normal :S 14 flmoIlL). In all patients bilirubin levels remained stable 
throughout the course of follow-up. Therefore data on bilirubin were 
not presented. 
During follow-up (median 1.5 years, range 1-4 years) the 
beneficial effects on symptoms and on the laboratory values were 
maintained. No major adverse effects of the treatment were reported by 
any of the patients. One patient (patient 3) experienced a short period 
of increased fatigue and itching after starting UDCA, which subsided 
within 6 months. 
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Table 2. Symptoms before and after institution of combined UDCA- and corticosteroid treatment 
(+ = present and - = absent). 
Patient nr. Pruritus Fatigue Arthralgia Total symptoms 
T (mths): 0 6 12 0 6 12 0 6 12 0 6 12 
1. + + 
2. + + 
3. + + 
4. + + + + + + 00 
(Jl 
5. 1 + + + + + + + + + 
6. + + + 
7. + + + + + + 
Symptomatic 
patients (n=): 3 1 1 5 2 2 2 1 0 7 3 2 
1 Interrupted UDCA-therapy after 9 months, situation at 9 months provided atT::;:;12. 
co 
'" 
Table 3. Absolute values of APh, AST and IgM and percentual decrease from baseline ( ) after 6 and 12 
months of combined therapy. 
Patient nr. APh AST IgM 
(nl :05 u/L) (nl ::;30 u/L) (nl ::;2.8 u/L) 
T (mths): 0 6 12 0 6 12 0 6 12 
1. 143 64 (55) 51 (64) 35 14 (60) 12 (66) 7.5 4.2 (44) 3.4 (55) 
2. 359 248 (31) 223 (38) 90 41 (54) 37 (59) 3.2 2.4 (25) 1.6 (50) 
3. 198 127 (36) 117 (41) 57 31 (46) 19 (67) 45 3.8 (16) 3.8 (16) 
4. 267 185 (31) 187 (30) 41 27 (34) 31 (24) 10.1 10.2 (+1) 10.7 (+6) 
5.' 198 64 (68) 71 (64) 39 15 (62) 15 (62) 3.6 3.5 (3) 3.4 (6) 
6. 355 194 (45) 188 (47) 61 40 (34) 36 (41) 4.4 3.8 (14) 3.7 (16) 
7. 199 159 (20) 127 (36) 39 27 (31) 26 (33) 3.4 2.5 (26) 
Median: 199 159 (36) 127 (41) 41 31 (46) 26 (59) 4.4 3.8 (15) 3.4 (16) 
Normal 
values (n=): 0 2 2 0 2 4 0 1 2 
1 Interrupted UDCA-therapy after 9 months, values at 9 months provided atT::;:12. 
Figure 1. 
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APh,AST Jnd IgM, expressed as mu!tiples of the upper limit of normal (N) during 4 years after 
prednisone treatment was added to UDCA, A normalization of AST and APh was achieved within 3 
months. 
Figure 2. 
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APh,AST and (gM, expressed as multiples of the upper limit of norillal (N) during 1.5 ycar after adding 
UDCA treatment to long-term inunullosuppressive therap)~ On combined treatment APh and AST 
normalized within 3 months, immediately rosc after stopping UDCA and ameliorated again after 
recommencing therapy. 
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The figures 1 and 2 illustrate the course of APh,AST and IgM 
before and during combined therapy. In patient 1 (figure 1) all 
laboratory parameters, except IgM, normalized after addition of 
prednisone to UDCA, and this was maintained up till the writing of 
this report, 4 years later. In patient 5 (figure 2) a complete biochemical 
normalization was achieved after addition of UDCA to prednisone. The 
patient interrupted UDCA intake because of lower abdominal pain, 
which she attributed to the UDCA treatment. A clear relapse occurred. 
Reinstitution ofUDCA again resulted in biochemical improvement. 
cause? 
I 
autoimmune 
attack 
IMMUNOSUPPRESSION --+ J 
cholestasis 
I 
retention of 
cytotoxic 
bile acids 
Figure 3. 
inflammation and 
, destruction of bile 
ducts and hepatocytes 
~ fibrosis 
t I 
UDCA cirrhosis 
Hypothesis on the pathophysiology of Primary Biliary Cirrhosis and sites of action ofUDCA and 
immunosuppressive therapy. From this model the synergistic effect of combined immunosuppre$sive- and 
bile add treatment is apparent. 
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DISCUSSION 
The results of this study suggest that the efficacy of either 
treatment with UDCA or prednisone in PBC can be enhanced by 
combining these two agents. All patients showed marked amelioration 
of biochemical abnormalities after initiation of combined therapy. The 
effect on bilirubin, a major prognostic variable, could not be evaluated 
because all patients had (near-)normal bilirubin levels at baseline which 
remained stable during follow-up. Furthermore, in this non-controlled 
study a remarkable effect on symptoms was suggested. 
As f.1r as we know, this is the first report describing the results of 
combined bile acid- and corticosteroid treatment. Both UDCA and 
prednisone have been evaluated in controlled trials and have 
documented beneficial effects in PBC (13-15). From these studies, and 
our own experience, we can conclude that a complete remission of the 
disease activity can rarely be achieved using single treatment with 
UDCA or prednisone (25). 
Our observations support the hypothesis that in PBC two distinct 
pathogenetic mechanisms are involved (figure 3).A hitherto unknown 
factor triggers a chronic auto-immune attack mainly directed against 
small bile ducts. Bile duct damage and eventually ductopenia result in 
cholestasis and, due to the toxic effect of retained bile acids, to secon-
dary liver damage. 
Prednisone may modulate the primary auto-immune mediated 
bile duct inflammation while UDCA probably mainly interferes at the 
level of the secondary bile-acid mediated liver damage by displacing 
endogenous toxic bile acids (26) as well as by protecting hepatocytes 
from bile acid toxicity (27,28). UDCA may also exert immunomodula-
ting effects (29,30). 
Immunosuppression alone might diminish or prevent further 
damage to bile ducts. However, due to existing irreversible structural 
liver damage, the process of secondary bile acid mediated liver damage 
could continue. When, on the other hand, administration of UDCA 
reduces mainly the damage caused by endogenous bile acids, the 
primary process leading to bile duct inflammation may remain operati-
ve. In general, patients in the pre-cirrhotic stages of PBC are likely to 
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benefit most by immunosuppressive therapy. However, in patients with 
compensated cirrhosis and normal bilirubin levels, suggesting the 
existence of residnal bile ducts, immnnosuppressive therapy may still be 
useful. This model might provide an explanation for the relatively low 
response to immunosuppressive therapy in PBC, for the partial effecti-
vity ofUDCA and for the synergistic effects ofUDCA and prednisone. 
Our observations have a preliminary character. Further long term 
controlled studies in larger groups of patients are indicated to confirm 
these results. It is also obvious that in further studies the effects on liver 
histology should be documented as well as the long term benefit-risk 
ratio of prednisone treatment. Although recent reports indicate that the 
danger of prednisone induced osteoporosis may have been overestima-
ted in the past (13,31), the influence oflong term prednisone treatment 
on bone mineral density and the prevention of osteoporosis should 
remain subjects for further studies. 
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SUMMARY 
Patients with compensated PBC (Child class Band C excluded), 
who had not achieved a disease remission after one year of 10 mg/kg 
ursodeoxycholic acid (UDCA) daily, were randomized to additional 
treatment with prednisone 10 mg plus azathioprine 50 mg daily (n= 18) 
or placebo (n= 18) for one year. The aim of this double-blind trial was 
to assess the short term benefits and risks of this combination therapy. 
Pruritus (p=O.OI), alkaline phosphatase, AST, IgM, procollagen-III-
propeptide improved significantly (all p<O.OOI) in the combination 
treatment group (UDCA/Prednisonel Azathioprine) as compared to the 
placebo group (UDCA/placebo/placebo).A cumulative histological 
score was used which decreased significantly within the combination 
treatment group (p=0.05). Lumbar Bone Mineral Content did not 
change in prednisone treated patients that were using cyclical 
etidronate. Three patients in the combination treatment group and two 
in the placebo gronp were withdrawn from treatment. Thus, in PBC, 
combination treatment of prednisone with azathioprine, improved 
pruritus, biochemical, fibrogenetic and histological parameters, on top 
of improvements already achieved with UDCA. Cyclical etidronate 
seems to prevent steroid induced bone loss. These results strongly 
encourage the evaluation of this triple treatment regimen in larger, 
long-term controlled trials. 
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INTRODUCTION 
UrsodeoAJ'cholic acid (UDCA) is currently considered the 
treatment of choice for Primary Biliary Cirrhosis (PBC) since it is safe, 
improves liver tests and slows disease progression (1-3). However, the 
potential ofUDCA to alter the natural course of the disease seems 
modest and complete remissions are achieved in less than 5% of patients 
(4).Therefore the combination ofUDCA with other drugs has been 
suggested as a logical next step (5,6). Theoretically, the addition of 
immunosuppressive drugs to UDCA is attractive because UDCA, 
interfering mainly with endogenous bile acid mediated liver damage, is 
unlikely to stop the primary imlllune damage (5,6). 
Both prednisone (7,8) and azathioprine (9,10) have been shown 
to be of some benefit in PBe. Prednisone has been deemed 
contraindicated due to its negative effect on bone status, which has 
been mainly documented in patients with advanced PBC and jaundice 
(11). Long term experience in our center, however, has documented 
that the negative effect oflow dose prednisone on bone density is 
limited in patients with compensated PBC (12). Moreover, drugs like 
bisphosphonates may prevent steroid associated bone loss (13-15). 
Azathioprine has not been accepted as therapy for PBC since the 
observed small benefit in life expectancy did not neutralize the fear for 
an increased risk of neoplasms (10). Long terlll follow up of patients 
with autoimmune hepatitis treated with low dose prednisone/azathiop-
rine indicates that this fear is unwarranted (16). 
Combining low doses of prednisone and azathioprine may lead to 
an increased immunosuppressive potential without enhancing the risk 
of side effects (6). To investigate the efficacy of combined UDCA, 
prednisone and azathioprine treatment, a I-year, multicenter, double-
blind, placebo-controlled trial was initiated in PBC patients who had 
not completely responded to UDCA alone (6).This analysis of the first 
36 patients was performed to assess the potential benefits and risks of 
the triple treatment regimen as compared to monotherapy with 
UDCA. 
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PATIENTS AND METHODS 
The main endpoint in this study is the achievement of a complete 
disease remission.To assess a difference in success rate of25% between 
both groups, with u=0.05 and a power of SO%, 60 patients are needed. 
However, in view of the prevailing reluctance regarding the use of 
corticosteroids in PBC, a preliminary report was planned, to document 
the potential benefits and risks of this treatment. 
As 32 evaluable patients are needed to detect a difference between 
means of one standard deviation and assuming a drop-out rate of 10%, 
it was determined that the first 36 patients entering the study would be 
subject of this interim analysis. 
All patients had an established diagnosis of PBC (17). Exclusion 
criteria were age >75 years, extrahepatic bile duct disease, (risk of) 
pregnancy, the use of other potential disease modifYing drugs within 6 
months prior to entry, known intolerance for prednisone or azathio-
prine, osteoporotic spinal fractures, systemic infections, a psychiatric 
history or cytopenia (defined as WBC<2.5 x 1O.9/L, platelets < 70 x 
10.9/L or Hb < 6 mmol/L), Patients with Child-Pugh classification B 
or C (IS) were excluded since they were considered unlikely to benefit 
fi'om medical treatment. 
All patients had been treated with UDCA (ca. 10 mg/kg/day) and 
after 1 year none of them had achieved a remission of the disease, 
according to the criteria of Beukers and Schalm (6). After stratification 
(presence versus absence of cirrhosis and center), patients were allocated 
at random to additional prednisone/azathioprine or placebo. Both 
clinicians and patients were unaware of the treatment allocation. 
Prednisone and identical looking placebo tablets were taken in a 
dose of 30 mg daily during the first month, 20 mg in the second 
month and 10 mg for the remaining period. One tablet containing 50 
mg azathioprine or placebo (Wellcome Pharmaceuticals, Utrecht, The 
Netherlands) was taken daily. 
All patients received calciumcarbonate 500 mg daily. Furthermore 
all, but 12 randomly assigned patients, were treated with 3 monthly 
cycles of etidronate 400 mg daily for 2 weeks (Procter & Gamble 
Pharmaceuticals, Rotterdam, The Netherlands). Patients with subnor-
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ma125-0H Vitamin D levels received 600.000 IU cole calciferol 
intramuscularly once. 
Patients visited the outpatient clinics monthly dnring the first 3 
months and at 3-monthly intervals thereafter. A physical examination 
including weight and blood pressnre measnrements was performed at 
each visit and patients were asked to grade itching and fatigue on a 
scale from 0-4 for the morning, afternoon, evening and night dnring 
the 5 subsequent days. 
Hemoglobin, white blood count, platelets, serum bilirubin, 
alkaline phosphatase (APh), aspartate aminotransferase (AST), albumin 
and inununoglobulin M (lgM) were assessed at each visit. In 24 patients 
[1sting serum aliquots were taken before start of the immunosuppressive 
treatment and at 3, 6 and 12 months for radioinmmnoassay of pro colla-
gen-III aminoterminal propeptide concentrations (P-III-P) using a 
conmlercially available kit (Orion Diagnostica, Espoo, Finland). All 
measurements were performed in the local laboratory except P-III-P 
(central laboratory University Hospital Rotterdam). 
Prior to the study and after 1 year Dual Energy X-ray 
Absorptiometry (DXA) measurements of Bone Mineral Content 
(BMC) of the lumbar spine (L2-L4) and femur neck as well as liver 
biopsies were performed. The liver biopsies were reviewed and staged 
according to Ludwig (19) by one pathologist (FJWtK), who was 
unaware of the treatment allocation and clinical state of the patients. 
Furthermore an overall histological score according to the method of 
Poupon et aJ. was used (20). 
Data are presented as means with standard errors of the mean, 
unless indicated otherwise. Laboratory data are expressed as multiples of 
the upper limit of normal (ULN) or percentage change from baseline. 
Changes in symptoms and laboratory parameters were analysed using 
Repeated Measnrements ANOVA (RmAnova) (21), after logarithmical 
transformation for bilirubin. BMC and histological scores were 
compared by non-parametric tests . .x'-tests were used for qualitative 
data. A two-sided p value ~ 0.05 was considered significant. All analyses 
were performed on an intention-to-treat basis. The study was approved 
by all local Medical Ethical Committees. All patients gave written 
informed consent. 
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RESULTS 
Entry characteristics in the UDCA/prednisone/azathioprine (U-
PA group, n=18) and the UDCA/placebo group (U-PL, n=18) were 
comparable (table 1). 
Table 1. Characteristics at entry. Data are given as numbers of patients or 
Ineans ± Standard Deviations. 
UDCA+ UDCA+ 
Prednisone/azathioprine (n= 18) Placebo (n = 18) 
Female 15 17 
Age (yrs) 53 ± 9 52 ± 11 
Bilirubin (x ULN) 1.1 ± 0.6 1.3 ± 0.7 
Albumin (x ULN) 1.2 ± 0.2 1.1 ± 0.1 
APh (x ULN) 3.0 ± 1.8 3.2 ± 1.6 
AST (x ULN) 1.3 ± 0.7 1.3 ± 0.7 
IgM (x ULN) 1.8 ± 1.0 2.0 ± 2.1 
P-III-P (N<4.2)* flgr/L 6.1 ± 3.5 4.9 ± 3.0 
Fatigue 12 16 
Pruritus 7 10 
Histological stage 2 1 
II 5 5 
III 6 7 
IV 5 5 
Bone mineral density 
- L2-L4 gr/clu2 1.017 ± 0.213 1.038 ± 0.177 
- fenlUr neck gr/cm2 0.863 ± 0.105 0.813 ± 0.156 
On etidronate 12 12 
*n ::::; 12 in each group, 
98 
xUU/ 
Bilirubin 
xUU/ 
6 
5.5 
5 T 
4.5 
4 
3.5 ! 
3 ~ 
2.5 r 
21 
Alkaline Phosphatase 
T T r ! T ! 
• 
I 
0.5 [l~~~p~re~d~n~I,~on~'~+~Az~al~h~,o~"n~.~v~/~;:J UDCA 
o 
·12 0 236 9 
months 
12 
1.5 ~ 0; [--'----:=:""""'-'-="""'e=~_\ 
o =~~,II==c=~=r====~~ 
-12 I 0 
Prednlllone + AzathioprIne vip 
UDCA 
2 3 6 9 12 
months 
xUU/ xUU/ 
3 4 
AST 3.5 IgM 
2.5 r 
I 3 2 
1 1 2.5 r r ~ 1.5 r·' 2 ~ : ~~ 1 I 1.5 • r 
0.5 -
PrednIsone + Azathlo fIne vI 0.5 t I Prednl,on. + Aze'hloprln. vip 
UDCA I UDCA 
0 o ~" I 
·12 0 2 3 6 9 12 -12 j 0 2 3 6 9 12 
months months 
Figure 1. 
Mean serum bilirubin,APh,AST and IgM during I year ofUDCA+prednisollciazathioprine (open 
squares) versus UDCA+placebo treatment (filled squares). Data are expressed as multiples of the upper 
limit of normal (ULN). Error bars indicate standard error of the meau. Changes from levels at 
randomization were significantly different (p<O.OOl) throughout the study for all parameters but bilirubin 
(p=O.3). Changes during the previous treatmcnt year with UDCA alone are ako shown.V/p in the 
medication bar indicates verum or placebo. 
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Figure 2. 
% change 
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Mean percentage change from baseline of serum procollagen-HI aminoterminal propeptide concentrations 
during UDCA+prednisonc/azathioprine (open squares) or UDCA+placebo treatment (filled squares). 
Changes are significantly different throughout the study period (p<O.OOl). Error bars indicate standard 
error of the mean. 
Belliftts 
A small though significant amelioration of itching in the U-PA 
group (-2.2 ± 3.1 points) was observed in comparison with the U-PL 
group (+6.8 ± 2.4; p=O.Ol).All patients with arthralgias in the U-PA 
group (n=4) noted amelioration during treatment and/or deterioration 
after stopping treatment while no change was reported in 6 patients 
with arthralgias receiving U-PL. 
Biochemical markel'S in the U-PA group improved significantly as 
compared to U-PL:APh -32 ± 5% vs.+4 ± 6%,AST -20 ± 7% vs. +24 
± 12% and IgM -21 ± 5% vs. -1 ± 3% (all p<O.OOI).The differences 
between changes were constant during the whole study period (figure 
1). Bilirubin remained stable in the U-PA group while it appeared to 
rise in the U-PL group, though the difference did not reach 
significance (p=0.3). The degree of the improvements did not differ 
between early (I-II) and late stage (III-IV) disease. These effects were 
achieved on top of decreases in APh,AST and IgM induced by the 
preceding UDCA treatment as compared to values at the start of 
UDCA (35,42 and 25% respectively; all p<O.OOI). 
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Biochemical remission, defined as normal AST, IgM and 
bilirubin, and APh 1.Sx ULN) was achieved in 3 U-PA patients and 1 
U-PL patient. In the U-PA group the incidence of normalizations of 
APh (6 vs. 3),AST (4 vs. 1) and IgM (4 vs. 1) tended to be higher but 
only reached significance for APh (p=0.04). In none of the patients (7 
in each group) elevated bilirubin levels normalized. 
P-III-P levels improved in the U-PA (-24 ± 6%) but not in the 
U-PL group (+2 ± 6%).The difference in change between both groups 
was significant (p<O.OOI) (figure 2).Abnormal P-III-P levels normali-
zed in 4 of8 U-PA patients but in none of 5 U-PL patients. Changes 
in P-III-P did not correlate with changes in bilirubin,AST or APh. 
Paired biopsies were available in 27 of the 36 patients (14 U-PA, 13 U-
PL). Six patients refused a follow up biopsy and 3 were referred for 
transplantation. Histological stage did not change significantly in either 
group. The cumulative histological score decreased significantly in the 
U-PA group by 1.8 ± 0.7 points (p=O.OS), and remained stable in the 
U-PL group (decrease 0.3 ± 1.1 point, p=0.8) (figure 3).These chan-
Score 
20 
15 
10 
5 ~. -------==::: 
o L_. __ p_~_O_.O_5_--:-_________ c=-c ___ ~P~O.8 
Entry 1 year Entry 1 year 
Figure 3. 
[ndividuai histological scores before and after 1 year ofUDCA+prednisonelazathioprine (left) or 
UDCA+placebo treatment (right). Ban indicate medians. The sum of the following items constitutes the 
histological score: fibrosis (graded 0-5), (pcri)portal inflammation (0-3), piece meaillecrosis (0-3), bile duct 
proliferation (0-3), lobular inflammation (0-3), focaillecrosis (0-2), cholestasis (0-3) and the ratio of the 
number of portal traCts without pre-existent bile ducts and the total number of portal tracts. 
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ges, however, did not significantly differ between both study groups. Of 
the individual constituents of the score the degree oflobular (p=0.03) 
and portal infiltrates (p=O.OI) improved significantly in the U-PA 
group. 
There was no clear difference between the groups in the number 
of patients showing hepatic deterioration using the criteria of 
Mitchison (7) (table 2). 
Table 2. Incidence of hepatic deterioration, using the MitchisOll criteria (7). 
Hepatic death 
Accepted for liver transplantation 
Doubling of bilirubin 
Albumin decrease of >6 giL 
De novo signs of portal hypertension 
(in casu ascites) 
Developtnent of cirrhosis 
No. of patients fulfilling 
one or lucre of these criteria: 
Risks 
UDCA+ 
Prednisone! azathioprine 
(n= 18) 
0 
1 
1 
0 
2 
2 
4 
UDCA+ 
Placebo 
(n=18) 
0 
2 
3 
0 
1 
3 
6 
Thirty-one patients were included in the evaluation of bone 
mineral content because in 5 patients no paired DXA measurements 
were available. In the U-PA group mean spinal BMC decreased signifi-
cantly in the patients without cyclical etidronate (-3.5 ± 0.6%, p=0.03, 
n=6), while no significant change was seen in the patients receiving this 
profylaxis (-1.1 ± 0.9, n=ll) and in U-PL treated patients with (+0.3 
± 1.5, n=8) or without etidronate (-1.2 ± 2.4, n=6) (figure 4). 
No significant changes in femoral BMC were noted. Data on other 
adverse effects are summarized in table 3. In the U-PA group more 
patients showed weight gain. Evident cosmetic changes were encoun-
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tered in 3 patients (marked weight gain, buffalo hump, ecchymoses, 
hair loss) and was coupled with increases in blood pressures in 2 of 
them. This led to lowering of the prednisone dose in 2 patients. Other 
intercurrent medical problems were not clearly predominant in any 
group. 
Within one month after entry 2 patients in the V-PA group were 
withdrawn from treatment because of general malaise and 1 after an 
episode of spontaneous bacterial peritonitis; the latter had progressed 
from Child-Pugh class A cirrhosis to class B in the month between 
establishing eligibility and the actual start of medication. Her disease 
remained progressive after treatment withdrawal and she was eventually 
referred for liver transplantation. In the V-PL group 2 patients were 
withdrawn because they showed disease progression and became 
eligible for liver transplantation (6 and 9 months). 
Figure 4. 
% change 
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Individual data on percentage change in bone mineral content of the lumbar \'crtebrae L2-L4 after I year 
oftreatmcnt for patients trcated with UDCA+preclllisone/azathioprine or UDCA+placebo, treated with 
or withollt etidronate. Bars indicate medians. 
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Table 3. Intercurrent and I or adverse events 
UDCA+ 
Prednisonel azathi oprine 
(n= 18) 
Weight gain :>:2.5 kg 
:>:5 kg 
Hypertension* 
Ecchymoses 
Hirsutislll 
Hairloss 
Non-insulin dependent Diabetes Mellitus 
Cytopenia ** 
Infections*** 
Pulmonary 
Urinary tract 
Parotis 
Spontaneous bacterial peritonitis 
Increased Of de 110110 gastrointestinal c0111plaints 
Peritoneal guarding e.c.i.(>laparotomy) 
Partial porto111esenterial thrombosis 
Transient ischemic attack 
Instable angina pectoris 
Tramnatic vertebral fracture 
General lllalaise 
Events leading to dose reduction of 
prednisone 
azathioprine 
Events leading to treatment withdrawal 
II 
8 
3 
2 
2 
2 
o 
2 
2 
o 
o 
I 
7 
o 
I 
o 
o 
o 
4 
2 
3 
UDCA+ 
Placebo 
(n= 18) 
3 
I 
o 
I 
o 
o 
I 
4 
o 
5 
I 
o 
I 
I 
4 
o 
2 
* Diastolic pressure increased to :>: 95 mm Hg or by :>: 20 n1111 Hg on 2 
consecutive visits. 
** WEC <2.5xI0.9/L and/or Platelets <70xl0.9/L. 
*** Antibiotic treatment instituted. 
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DISCUSSION 
This study shows an additional effect of combination treatment of 
low dose prednisone and azathioprine on itching, serum markers of 
liver cell damage, cholestasis, inul1une activity, fibrogenesis and 
histology in PBC patients who had been receiving UDCA during at 
least one year. Our data indicate that side effects of this triple therapy 
are acceptable and steroid induced bone loss can be prevented by 
cyclical etidronate. 
The effects of the combined immunosuppressive treatment were 
more pronounced than those reported for azathioprine alone (9,22), 
and were comparable to those found by Mitchison et aJ. in a controlled 
trial with prednisolone (23). The observed effects were achieved in 
addition to marked improvements already obtained with UDCA, 
confirming our earlier uncontrolled data (8). 
Bilirubin, a major prognostic parameter in PBC, remained stable 
during triple treatment. P-lII-P, a serum marker of fibrogenesis (24-26) 
which has also been reported by several groups to be of prognostic 
significance in PBC (27-31) normalized in 50% of patients receiving 
triple therapy. In patients receiving UDCA, P-III-P may be a more 
appropiate prognostic marker than bilirubin since UDCA may directly 
increase bilirubin excretion (29), but does not seem to affect P-III-P 
levels (32). 
The observed histological improvement ofliver inflammation is 
in agreement with previous findings with prednisolone alone (23). 
Obviously larger trials oflonger duration are required to establish 
whether the triple regimen can prevent histological progression. 
The adverse effect of corticosteroids on bone mass has limited 
their use in PBC, although low dose prednisone has been shown to be 
relatively safe in patients with non-advanced disease (7,12).The 
maximal bone loss during corticosteroid treatment occurs during the 
first year of therapy (23,33,34). Our data indicate that etidronate may 
prevent this initial bone loss which is in agreement with studies in 
other diseases (13-15).Whether this approach will prevent bone loss 
during long term corticosteroid treatment remains to be established. 
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In the triple treatment group weight gain occurred frequently, 
which may have been related to the relatively high initial prednisone 
dose. A minority of these patients experienced significant cosmetic 
changes and increased blood pressures. The inmlUnosuppressive 
treatment was not clearly associated with infections or other intercur-
rent medical problems. As all adverse effects leading to treatment 
withdrawal occurred during the first weeks, diminishing the high 
induction doses of prednisone in future studies should be considered. 
Other measures such as appropiate dietary advice and timely dose 
adjustments could further decrease the incidence of adverse effects. 
Previous studies, combining UDCA with colchicine, have failed 
to show additional benefit of colchicine (35,36).Additive beneficial 
effects of methotrexate to UDCA have been reported but the serious 
side effects of methotrexate, especially interstitial pneumonitis, limit 
further exploration of this combination (37-39). 
We conclude that there is a synergistic beneficial effect oflow 
dose prednisone-azathioprine treatment with UDCA in PBe. The 
short term benefit/risk ratio appears positive and justifies continued 
studies to establish the efficacy of the triple regimen on the long term 
course of the disease. 
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SUMMARY 
It has been suggested that soluble intracellular adhesion molecule-
1 (sICAM-l) may be a useful marker of disease activity in inflammatory 
and immune diseases. Here we determined sICAM-l levels in 24 
patients with Primary Biliary Cirrhosis (PBC) during 12 months of 
ursodeoA),cholic acid (UDCA; 10 mg/kg/ day) mono therapy followed 
by a 6-month period of, randomly assigned, additional treatment with 
a combination of azathioprine (50 mg/ day) and prednisone (30 mg/ day 
first month, 20 mg/ day second month, 10 mg/ day maintenance) or 
matching placebos. sICAM-l levels were assessed by ELISA, at baseline, 
12,15 and 18 months. Baseline levels of sIC AM-l correlated with 
histological stage, bilirubin and ASAT. sICAM-l concentrations fell by 
a median of 20% during UDCA monotherapy (p<0.0004).The 
addition of azathioprine and prednisone during 6 months resulted in 
further reduction of sIC AM-I levels by a median of25%, while they 
remained stable in the placebo group (p<O.OI). Reductions in sICAM-
1 were accompanied by improvements in biochemical liver tests but not 
by changes in the lymphocyte activation marker, soluble interleukin-2 
receptor. We conclude that sI CAM-l levels reflect hepatic inflammatory 
activity and fall during UDCA monotherapy.Additional treatment with 
a combination of/ow dose prednisone and azathioprine leads to further 
decreases in sICAM-1. Larger, long term studies should further define 
the usefulness of monitoring sICAM-llevels in the treatment ofPBC, 
particularly with regard to disease progression. 
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INTRODUCTION 
Intercellular adhesion molecule-l (ICAM-l) is a member of the 
immunoglobulin supergene fanuly of adhesion molecules (1). It is 
expressed on the surface membranes of a variety of cells in many diffe-
rent inflanmlatory and immunological disorders (2). Structurally, it is a 
sialylated glycoprotein with a molecular weight of about 95 kDa, 
consisting of five extracellular inm1l1noglobulin like domains, a single 
transmembrane region and a short cytoplasnuc tail (3). 
Functionally, ICAM-l binds to its corresponding ligands, LFA-l 
(CD11a/CD18) and MAC-l(CD11b/CDI8) (4,5). In doing so, 
ICAM-l acts as a co-stimulatory £1ctor forT-ceil activation (6) and also 
mediates the nugration ofleucocytes from the circulation, through the 
endothelium and basement membrane, to home in, and to adhere to 
target structures or other inmlUne cells (7). 
In health, there is nunimal membrane surface expression of 
ICAM-l in the liver (8,9). In PEC, this expression is increased on 
interlobular bile ducts, proliferating bile ductules, hepatocytes and 
infiltrating leucocytes (8,10). 
A soluble form ofICAM-l (sICAM-l), identical in extracellular 
domains but lacking the transmembrane components of membrane 
bound ICAM-l, has been identified (11). Significant elevations of 
sICAM-l levels have been described in a variety of inflammatory and 
autoimmune diseases including PEC (12-15). In PEC, correlations of 
sICAM-llevels with biochenucalliver tests, histological stage and 
disease severity, as assessed using the Child-Pugh classification have 
been found (13,14). It has been proposed that measurement of 
circulating sI CAM -1 levels may be useful in the investigation and 
monitoring of immune and inflammatory disease such as PEC (13,16). 
Despite uncertainty abont its long term efficacy, the current medical 
treatment of choice for PEC is ursodeoll.],cholic acid (UDCA)(17-19). 
The exact mechanisms of action ofUDCA remain unclear. It has been 
suggested that UDCA acts by reducing the damage caused by toxic 
endogenous bile salts (20,21).There is also some evidence that UDCA 
may have inununomodulating properties (22-25). As both immune 
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Table 1. Patient characteristics at entry for the two groups to be 
randomized to treatment with prednisone/azathioprine or 
placebos at T=12. Laboratory parameters given as mean ± SEM. 
To be randomized to: 
Age in years, mean (range) 
Male I female 
Stage 
II 
III 
IV 
Bilirubin (flmoIlL) 
Normal range 4-14 
Alkaline Phosphatase (U/L) 
Normal range 25-75 
Alanine aminotransferase (U IL) 
Normal range 5-30 
Aspartate aminotransferase (U/L) 
Normal range 5-30 
IgM (giL) 
Normal range 0.6-2.8 
Albumin (giL) 
Normal range 36-48 
UDCAIPREDI AZA 
11=12 
112 
54 (41-66) 
3/9 
o 
2 
5 
5 
18 ± 3 
306 ± 35 
86 ± 8 
60 ± 5 
4.8± 0.5 
43 ± 1 
UDCAIplaccbos 
n=12 
55 (31-66) 
I I 11 
4 
3 
4 
15 ± 2 
335 ± 49 
95 ± 14 
68 ± 8 
6.1 ± 1.7 
42 ± 1 
mechanisms and bile salt mediated damage are likely to playa central 
role in the pathogenesis ofPBC (26), it is not unreasonable to suggest 
that a combination ofUDCA with immunosuppressive agents may be 
more efficacious (27). Corticosteroids and azathioprine have both been 
shown to be of some benefit in PBC (28,29). Combining low doses of 
prednisone and azathioprine is thought to lead to an enhanced efficacy 
and a lower risk of side effects (30). 
The aims of this study were first to determine the effects of 
UDCA and immunosuppressive treatment (prednisone and 
azathioprine) on sICAM-l levels in PBC Secondly, to compare the 
effects on slCAM-l with those on other parameters of disease activity 
(biochemical liver tests, IgM) and soluble interleukin-2 receptor (sIL-
2R), a marker of lymphocyte activation. 
SUBJECTS AND METHODS 
Twenty-four patients, with an established diagnosis of PBC 
according to Taal et al.(31) were recruited at the University Hospital 
Rotterdam, in the context of a multicentric project aiming at the 
systematic, prospective evaluation of new treatment options in PBCAll 
patients had positive antimitochondrial antibodies, liver biopsies consis-
tent with PBC and absence of biliary obstruction on ultrasonography. 
Patients with Child-Pugh class Band C disease were excluded from the 
study.The patients received UDCA (10 mg/kg) for the 18 month 
duration of the study. After 12 months ofUDCA, none of the patients 
had achieved inactivation of the disease, i.e. absence of symptoms and 
biochemical abnormalities (30), and were subsequently randomized to 
receive additional treatment with a combination of azathioprine (50 
mg/ day) and prednisone (30 mg/ day for the first month, 20 mg/ day for 
the second, followed by 10 mg/day maintenance), or matching place-
bos. None of the patients were treated with any other drugs known to 
affect sl CAM -1 at the time of the study. 
The study protocol was approved by the local hospital ethical 
committee and informed written consent was obtained from all 
subjects. 
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Table 2. Biochemical parameters during 1 year ofUDCA and during 6 months of additional treatment with 
prednisone/azathioprine or placebos.Values given as mean±SEM. 
1 year UDCA alone UDCA/PRED/AZA UDCA/placebos 
(n=24) (n=12) (n=12) 
Baseline T=12 T=12 T=15 T=18 T=12 
Bilirubin 16±2 15±1.3 16±2 15±2 16±2 16±2 
APh 319±30 234±27' 239±46 154±342 152±322 241±32 
ALAT 90±8 46±6' 46±3 41±6 40±4 49±12 
ASAT 63±5 35±3' 36±3 29±3' 27±32 36±6 
IgM 5.5±O.9 3.9±O.7' 4.0±O.6 3.1±O.44 2.9±O.33 4.4±1.3 
1 p<O.OOl for difference from baseline; 
2: p<O.OOS for difference from baseline and p<O.OOl for difference in percentage change bet\¥een groups; 
3 p<O.Ol for difference from baseline and p<O.OOl for difference in percentage change betvveen groups; 
-I p<O.03 for difference in percentage change between both groups. 
T=15 
16±3 
212±26 
46±9 
36±6 
4.5±1.3 
T=18 
17±3 
235±34 
52±12 
40±8 
4.6±1.4 
Serum bilirubin, alkaline phosphatase (APh), aspartate and 
alanine aminotransferases (ASAT and ALAT), Immunoglobulin M 
(IgM) and albumin were determined at baseline, and at 12, 15 and 18 
months. Serum aliquots were stored at -200 C untill the assessment of 
sICAM-l and sIL-2R levels. In 5 patients, baseline serum aliquots were 
not available for analysis. sICAM-l and sIL-2R levels were also measu-
red in 17 healthy controls. 
Measurement of sICAM-1 and sIL-2R 
Follow up sera that belonged to the same patient were tested 
together. The investigators performing the measurements were unaware 
of the treatment allocation. Levels of sIC AM-I were measured in 
duplicate using an enzyme linked immunosorbent assay (ELISA) kit, 
commercially available from British Bio-technology Products (Ox-
ford,UK). In brief, the method involved the binding of sIC AM-I 
present in serum or standard to antibodies absorbed on to microwells. 
Unreacted sample components were removed by washing. A horse-
radish peroxidase-conjugated monoclonal antibody with neutralizing 
properties against ICAM-l was used to bind to ICAM-l captured by 
the first antibody. After washing, and addition of tetra-methylbenzidine, 
the reaction was stopped and the absorbance of samples and ICAM-l 
standards were read using an Anthos 2001 reader (Denley Instruments, 
Billinghurst, UK) set at 450 nm with a correction wave length of 620 
nm. Inter and intra assay variation was less than 10%. 
Levels of sIL-2R in sera were measured in duplicate by ELISA 
(Genzyme Diagnostics, Cambridge, MA, USA). The method involved 
the binding of sIL-2R present in serum or standard to antibodies 
absorbed on to microwells. Unreacted sample components were 
removed by washing. A peroxidase-labelled streptavidin reagent was 
added which attaches to biotin in the immune complex on the plate. 
After incubation, further washing and addition of tetra-
methylbenzidine, the reaction was stopped and the absorbance of 
samples and IL-2R standards were read using an Anthos 2001 reader 
(Denley Instruments, Billinghurst UK) set at 450 nm. Inter and intra 
assay variation was less than 10%. 
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Statistical tIlethods 
Differences within and between groups were tested by Wilcoxon's 
signed rank and rank-sum tests. Correlations were examined by 
Spearman's rank correlation. A p :50.05 was considered significant. The 
analysis was performed according to the intention to treat principle. 
RESULTS 
Patient characteristics at entry of the patients to be randomized to 
prednisone/azathioprine and placebo were comparable (table 1). One 
patient in the prednisone/azathioprine group stopped this treatment 
after 1 month because of general malaise. 
When dividing patients in early (stage III!) , stage III and stage IV 
disease (32), baseline sICAM-l levels were higher in all stages (III!: 
median 484 ng/ml, range 298 to 2039, p<O.OOI; III: 878, range 266 to 
1348, p<O.OOI; IV: 1663, range 746 to 2344, p<O.OOOI) as compared 
to healthy controls (median 259 ng/ml, range 156 to 499). sICAM-l 
levels correlated with the stage of the disease (R, 0.54, p<0.01) (figure 
1), bilirubin (R, 0.53, p<0.02),ASAT (R, 0.60, P<0.005) and ALAT 
(R,=0.44, p<0.05). 
sICAM-lleveis fell during the 12 months ofUDCA therapy by a 
median of20% (range -55 to +6%) fi'Om a median of 1137 (range 266 
to 2344) to 895 (range 214-2389) ng/ml (p<0.0004) as shown in figure 
2. APh,ASAT,ALAT and IgM also improved during this period (table 
2).The observed changes in sICAM-1, liver tests and IgM during 
UDCA monotherapy were comparable for the patients subsequently 
randomized to either prednisone/azathioprine or placebos. 
Further decreases in sICAM-l levels were found in patients 
receiving the additional immunosuppressive treatment. In this group, 
levels at both 15 (median 588 ng/ml, range 228 to 2579, p<0.05) and 
18 months (554, range 238 to 2080, p<O.OI) were significantly lower 
than at 12 months (828, range 214 to 3190). In the group on continued 
UDCA monotherapy, levels were not significantly different at 12 
(median 939 ng/ml, range 239 to 2526), 15 (1080, range 225 to 3385) 
and 18 (966, range 224 to 3174) months. These results are shown in 
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Figure 1. 
Serum sICAM-I lewis in healthy controls, patients with early stage (stages UII), stlge 1lI and stage IV 
PBC.The bars indicate the medians. siCAM-l levels correlated with histological stage of disease (R,=O.54, 
p<O.OI). 
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Figure 2. 
Eflect of 12 months UDCA therapy on sICAM-lleYels in PBC.The bars indicate the medians. 
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months. The very high values of one patient ill each group have not been shown for reasons of scale; the 
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Controls SUgesl/U SUgelli 
Serum sIL-2R levels in healthy controls, patients with early stage (stages IIII), stage III and stage IV PBe. 
The bars indicate the medians. There was no correlation between sIL-2R levels and histological stage. 
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figure 3.The percentage change between the treatment and placebo 
groups differed significantly atT=15 (-19%, range -41 to +30% vs. +3, 
range -41 to +60%, p<0.03) and T=18 (-25%, range -49 to +13% vs. 
0%, range -21 to +71%, p<0.01). In the treatment gronp ASAT,APh 
and IgM also improved significantly (table 2). 
sIL-2R levels were significantly higher in early (median 2562 pg/ 
nu, range 1378-2882, p<0.005), stage III (1709, range 669-
2639,p<0.005) and stage IV (2046, range 1289 to 4326, p<0.0002) 
PBC compared to healthy controls (692, range 250 to 1500) (figure 4). 
sIL-2R levels did not correlate with sICAM-1levels in either PBC 
patients or healthy controls. Also no correlations with stage or bio-
chemical disease markers were detected. Treatment with UDCA did 
not significantly affect sIL-2R levels (median 2046 pg/nu, range 669 to 
4326 at baseline vs. 1845, range 587 to 10.123 at 12 months). Addition 
of prednisone/azathioprine led to a reduced sIL-2R level at 15 months 
(1249 pg/nu, range 683 to 2253, p<0.05) but not at 18 months (1429, 
range 851 to 2628, p=NS) as compared to 12 months (1523, range 587 
to 2842). Levels in the continued UDCA monotherapy remained stable 
(T=12: median 2050 pg/nu, range 888 to 10.123;T=15: 1924, range 
786 to 6564;T=18: 1979, range 624 to 6042). Differences in percenta-
ge change between both groups were not significant at any moment. 
No correlations were found between the percentage change in 
the standard disease parameters, sICAM-1 and sIL-2R during UDCA 
or prednisone/azathioprine treatment. Alterations in sICAM-1 and sIL-
2R were independent of histological stage or initial liver test results. 
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DISCUSSION 
We found that treatment ofPBC patients with UDCA during 12 
months resulted in a significant lowering of circulating sICAM-lleveis. 
Further reduction in sI CAM -1 was achieved by the addition of 
immunosuppressive therapy in the form of prednisone and 
azathioprine. Decreases in sICAM-l were accompanied by 
improvements in serum liver tests and IgM but not in the T-Iymphocyte 
activation marker, sIL-2R. 
The observed correlation of sIC AM-I with histological stage and 
transaminases in untreated PBC patients were consistent with our 
previous observations (13). However, in the present study,APh did not 
correlate with sICAM-l, while bilirubin did. These differences may be 
accounted for by the number and the disease stage of the patients 
studied; a higher proportion of patients with late stage disease was 
included in this study. 
Uncontrolled data had already indicated a reduction of sICAM-l 
levels by immunosuppressive treatment - mostly consisting of 
corticosteroids with or without another immunosuppressant - in a 
variety of other non-hepatic (33,34) as well as hepatic inmlUne disor-
ders, such as hepatic allograft rejection and autoimmune hepatitis 
(35,36). In PBC,Thomson et al reported a fall in sICAM-l in 2 
patients during immunosuppression with FK506 (14). In contrast, no 
effect of methotrexate on sICAM-l was found in 8 patients (37). In all 
of these conditions falls in sICAM-l indicated a favourable treatment 
response. As for UDCA, we know of only one abstract reporting a fall 
in sICAM-lleveis during therapy in 8 of14 patients with various 
cholestatic disorders, including PBC (38). 
The serum level of sIC AM-I represents an equilibrium between 
its formation and its excretion. The production of sIC AM-I is 
stimulated by a variety of cytokines and mediators including 
lipopolysaccharide, IL-la, TNF-~ and Interferon-y (39-43). The 
observed fall in sICAM-l during the treatment with inullunosup-
pressive agents probably represents a decrease in inflanmlatory activity. 
This may also be true in the case ofUDCA, as there is some evidence 
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that UDCA may have imll1unomodulatory properties (22-25).As for 
excretion, it has been demonstrated that sICAM-l is present in bile 
(28) and that UDCA can improve hepatobiliary excretion in PBC (44). 
It is conceivable that UDCA may also decrease sICAM-llevels by 
reducing cholestasis and increasing hepatic excretion of this molecule. 
However, the lack of a correlation between changes in bilirubin and 
APh and sICAM-l during UDCA therapy suggests that this is not the 
sole explanation. 
In contrast to membrane bound ICAM-l, the source, mechanism 
of formation and pathophysiological role of sI CAM -1 are less clear. 
With regard to its pathophysiological role, it has been proposed that 
sICAM-lmay regnlate leucocyte-endothelial interaction by competing 
for binding ligands with membrane bound ICAM-l (11). It is also 
possible that sICAM-l may be acting like a cytokine, providing a 
signalling effect similar to the co-stimulatory effect of membrane 
bound ICAM-l (34). This being the case, the fall of sICAM-l during 
treatment may be of direct pathogenetic relevance. It has previously 
been demonstrated that sICAM-l can be biologically active. III vitro, 
recombinant forms of sIC AM-I are capable of interfering with antigen 
specific T cell proliferation in a dose dependent fashion (45). Moreover, 
sICAM-l has been found to intetfere with the recognition of tumour 
cells by IL-2 activated lymphocytes (39) and to inhibit the infection of 
cells by rhinovirus (46). 
With regard to its formation, a couple of mechanisms have been 
proposed. sICAM-lmay be a product of proteolytic cleavage of 
membrane bound ICAM-l close to the cell membrane, as has 
previously been shown for other cell surL1ce tllolecnles (48). This may 
be supported by the finding that ICAM-l expression on lnterferon-y 
stimulated tumour cells declined after an initial increase and the decline 
was accompanied by an increase in the soluble ICAM-l form (49).An 
alternative hypothesis is that sICAM-l is formed from an alternatively 
spliced messenger RNA (11). However, there is as yet no experimental 
evidence to support this hypothesis. 
There are several possible sources of sIC AM-I in PBC,While 
release of sICAM-l by cultured bilialy epithelial cells could not be 
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substantiated (15), human hepatocytes have recently been shown to first 
express ICAM-I and subsequently sICAM-I, during cytokine stimula-
tion (14). Furthermore, activated endothelial cells near the inflamma-
tory sites may also shed sICAM-l (42). 
Activated lymphocytes, which can also be induced to produce 
sICAM-l ill lIitro, may be yet another source (15). However, the lack of 
correlation between the levels of sIC AM -1 with markers oflymphocyte 
activation such as lymphocyte IL-2R expression (13), sIL-2R and ~2-
microglobulin (15), as documented by us as well as by others, argue 
against this hypothesis. Moreover, in the present study, falls in sICAM-l 
were not parallelled by rednctions in sIL-2R levels during either 
UDCA or immunosuppressive therapy. 
The absence of an effect of immunosuppressive therapy on sIL-
2R was unexpected. However, sIL-2R, although a marker of systemic 
lymphocyte activation, may not accurately reflect the degree oflocal 
(hepatic) activity (50). Furthermore, in PBC there appears to be an 
aberrant IL-2R regulation as indicated by the finding of an increased 
IL-2R expression on unactivatedT lymphocytes (51). 
In PBC, circulating sI CAM -1 is a marker of disease severity and 
appears to reflect the degree of hepatic inflammatory activity. sICAM-l 
levels decreased during UDCA therapy, suggesting an inllllunomodu-
latory effect. Further reduction was achieved by the addition of 
inllnunosuppressive therapy with combined prednisone and azathiop-
rine. Further clarification of the significance of sICAM-l in PBC is 
needed, particularly as an indicator of prognosis and treatment efficacy 
in the long run. 
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SUMMARY 
Recently promising disease modifYing effects of low dose 
corticosteroid treatment in Primary Biliary Cirrhosis (PBC) have been 
reported. However, steroid-induced bone loss constitutes a potential 
drawback of this treatment option. 
To assess whether etidronate can reduce bone loss during 
corticosteroid treatment, 12 PBC patients (all Child-Pugh Class A), 
treated with prednisone in the context of a I-year placebo-controlled 
trial with prednisone (maintenance dose 10 mg daily) and azathioprine 
(50 mg daily), were randomized to receive either cyclical etidronate 
(400 mg daily, during 2 weeks) alternated with calcium 500 mg daily 
during 11 weeks, or calcium alone. Bone Mineral Content (BMC) was 
measured in the lumbar spine and the femoral neck by Dual Energy 
X-ray Absorptiometry before and after 3 and 12 months of treatment. 
Markers of bone formation (serum osteocalcin, procollagen-I-
propeptide) and bone resorption (urinary deOJl.)'pyridinoline and cal-
cium) were also monitored. 
The mean lumbar BMC did not decrease significantly in the 
patients taking etidronate+calcium, in contrast to patients treated with 
calcium alone (-0.8 vs. -3.5%; p=0.03). Changes in femoral BMC and 
markers of bone turnover did not significantly differ between both 
groups. No adverse effects of etidronate were noted. 
In conclusion, cyclical etidronate appears to prevent bone loss 
associated with prednisone treatment in patients with PBe. These 
results may encourage further evaluation of long-term prednisone 
treatment in PBe. 
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INTRODUCTION 
Primary Biliary Cirrhosis (PBC) is a chronic, potentially f.1tal 
cholestatic liver disease characterized by non-suppurative destruction of 
small and intermediate bile ducts, predominantly affecting middle-aged 
women (1).The disease is associated with osteoporosis and patients 
seem to lose bone at an annual rate twice that of healthy controls (2 vs. 
1 %) (2). Impaired osteoblast function as well as increased bone 
resorption have been proposed as potential underlying mechanisms (3). 
Based on findings in patients with advanced disease, 
corticosteroid treatment is considered contraindicated for PBC, due to 
fear of further acceleration of bone loss (4). However, the interest in 
corticosteroids as a treatment option in PBC has been revived. In 
accordance with our experience (5), Mitchison ct aI., who performed a 
placebo-controlled study with corticosteroids in PBC, recently 
reported beneficial effects regarding disease activity, although at the cost 
of a doubling of bone loss during the first year of treatment (6,7). 
To enable the safe use of corticosteroids in PBC, measures to 
prevent bone loss acceleration are needed. Bisphosphonates, e.g 
etidronate, are inhibitors of bone resorption (8) and have been shown 
to prevent bone loss in postmenopausal women (9,10) as well as in 
patients using corticosteroids for other non-hepatic diseases (11-13). 
This controlled pilot study was initiated to assess whether cyclical 
etidronate can reduce bone loss in corticosteroid treated PBC patients. 
PATIENTS AND METHODS 
Twenty-four patients with an established diagnosis ofPBC (14), 
participating in a double-blind, placebo-controlled trial with 
prednisone/azathioprine were eligible for this study. Exclusion criteria 
were: Child-Pugh Class B or C; previous treatment with estrogen 
replacement, bisphosphonates, fluoride or calcitonin; renal impairment; 
other gastrointestinal diseases; insulin dependent diabetes mellitus; 
pituitary dysfunction; hyperparathyroidism; alcoholism; inmlObility; age 
over 70 years; presence of osteoporotic vertebral fractures (i.e. >20% 
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reduction in vertebral height). 
The study was approved by the local medical ethical committees 
of both participating hospitals and patients gave written informed 
consent. 
As we did not know which patients received prednisone/ 
azathioprine or placebo, all patients were randomly allocated, after 
stratification for sex and pre/postmenopausal state, to receive either 3-
monthly cycles of etidronate 400 mg daily during 2 weeks (taken with 
water with 2 hour intervals fium meals) alternated with 11 weeks of 
1250 mg calciumcarbonate (=500 mg elementary calcium) or 
calciumcarbonate alone (Procter & Gamble Pharmaceuticals, Rotter-
dam, The Netherlands). Both regimens were started 1 month before 
entry in the trial with immunosuppressives and maintained during the 
whole study period. 
The immunosuppressive treatment consisted of 30 mg prednisone 
during the first 4 weeks, 20 mg during the following 4 weeks and 10 
mg daily thereafter for 40 weeks, combined with 50 mg azathioprine 
daily (Wellcome Pharmaceuticals, Utrecht, The Netherlands). All 
patients had been receiving 10 mg/kg/ day ursodeoll.),cholic acid 
(UDCA) for at least 1 year and this treatment was continued. 
An overview of the study is presented in figure 1. At entry and 12 
and 52 weeks thereafter bone mass measurements were performed by 
Dual Energy X-ray Absorptiometry (DXA) of the 2nd, 3th and 4th 
lumbar vertebrae and the left femoral neck using a Lunar DPX-L 
scanner (Lunar Radiation, Madison, WIS, USA). In our laboratory the 
coefficients of variation in healthy females for the lumbar and femoral 
measurement are 1.1 and 1.4% respectively. All measurements were 
performed by one technician. Before and after the study radiological 
examinations of the thoracic and lumbar spine were performed 
confirming the absence of fractures in the regions of measurement. 
Fasting blood and 2-hour urine samples were collected according 
to the study overview (figure 1). Apart fi'om standard liver tests, serum 
albuntin and calcium, two serum markers of bone formation, i.e. 
procollagen I carboll.),terminal propeptide (PI CP) and osteocalcin, were 
radioimmunologically assayed by means of commercially available kits 
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(Orion Diagnostica, Espoo, Finland; Incstar Corporation, Stillwater, 
MN, USA respectively).As markel'S of bone resorption the urinary 
concentrations of deo>.!,pyridinoline cross-links (d-pyr) (competitive 
enzyme immunoassay kits, Metra Biosystems, Palo Alto, CA, USA) and 
calcium were determined and corrected for urinary creatinine 
concentrations (15). Serum 25-hydro>.)'Vitamin D3 [25-(OH)DJ, 1,25-
dihydro>.!,vitamin D3 [1,25(OH),DJ and parathyroid hormone (PTH) 
were determined with commercially available kits (Incstar Corporation, 
Stillwater, MN, USA) at entry and at 1 year.Vitamin D supplementa-
tion was to be administered in case of subnormal 25-(OH)D at entry, 
but levels were normal in all patients. 
Bone mass data are given as Bone Mineral Content (BMC) in 
gram Hydro>,!,apatite per centimeter (gHAI cm), Bone Mineral Density 
(BMD) in gHAI cm2 and Z-scores, i.e. the number of standard 
Study medIc at/on: 
1 0 mg prednisone and 50 mg azathIoprine Id 
Identical placebos 
UDCA 10 mgfd 
ExamInations: 
DXA x x X 
Serum x x x x x 
Urine x x x x 
Time axIs 
In weeks: 0 4 6 12 26 52 
Figure 1. 
Study ovelView. "R" indicates randomization. 
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Table 1. Characteristics at entry of prednisone/azathioprine treated 
patients (means ± Standard Deviation or number of patients). 
etidronate no etidronate 
(n=6) (n=6) 
Female/Male 5/1 412 
Pre/Postmenopausal 114 212 
Histological Stage lIIl 1 
IIIIIV 6 5 
Age (yrs) 57 ± 11 49 ± 6 
Bilirubin (N 2-14 IlmoUL) 17 ± 8 15 ± 5 
APh (N 25-75 u/L) 147 ± 44 338 ± 131 I 
Albumin (N 36-48 giL) 42 ± 3 44 ± 2 
BMD L2-L4 (gr HAl ctn') 1.096 ± 0.20 1.132 ± 0.17 
Z-score 0.0 ± 0.9 -0.5 ± 1.2 
BMD femoral neck (gr HAl ctn') 0.885 ± 0.10 0.884 ± 0.07 
Z-score 0.0 ± 0.5 -0.5 ± 0.8 
I p<O.Ol N = nonnal range 
deviations that the individual BMD differs from the mean BMD of age 
and sex matched healthy controls. 
Follow up data are presented as the means with standard errors of 
the mean of the actual values and/or percentual changes from baseline, 
unless indicated otherwise. Paired and unpaired t-tests were used to 
compare differences. A two-sided p-value oS 0.05 was considered signi-
ficant. The data were analysed according to the intention-to-treat 
principle. 
RESULTS 
Characteristics at entry of the prednisone/azathioprine treated 
patients are presented in table 1. There were 6 patients in each group. 
Bone status was relatively normal, as apparent from the Z-scores. The 
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Table 2. Bone Mineral Content (grams hydroxyapatite/em) and percen-
tage change from baseline (in italics) in the lumbar spine and 
fetnoral neck during 1 year of prednisone treatment. 
Tin etidronate 
weeks (n=6) 
BMC L2-U 
Baseline 47.6 ± 6.2 
12 47.6 ± 5.8 
% change +1.0±1.0 
52 47.2 ± 6.0 
% change - 0.8 ± 0.9* 
BMC femoral neck 
Baseline 4.5 ± 0.4 
12 4.6 ± 0.5 
% change +0.1±3.2 
52 4.4 ± 0.4 
% change - 2.3 ± 3.3 
Data given as B1eans ± SEM 
:j: Significantly different from baseline (p=O.006) 
* Significantly different between groups (p=0.03) 
133 
no etidronate 
(n=6) 
50.9 ± 4.4 
50.0 ± 3.8 
-1.3±1.3 
49.0 ± 4.0:j: 
- 3.5 ± 0.6* 
4.7±0.1 
4.6 ± 0.2 
- 2.4 ± 2.5 
4.6 ± 0.1 
- 2.6±2.5 
patients were mostly stage HIIIV, but had rather mild disease as 
indicated by the biochemical disease markers. The mean alkaline 
phosphatase (APh) was lower in the group receiving etidronate. One 
patient in the etidronate group stopped the prednisonelazathioprine 
medication 1 month after the start of the inl1llunosuppressives, because 
of general malaise. All patients completed the study and no adverse 
effects of etidronate were noted. 
In table 2 changes in BMC during prednisone treatment are 
reported.Vertebral bone loss was less in patients taking etidronate 
compared to those without etidronate (-0.8% ± 0.9 vs. -3.5% ± 0.6; 
p=0.03) (Figure 2). The mean difference in change between both 
groups was 2.7% (95%-confidence interval: 0.4 to 5.0%). Using multi-
ple regression, the change in BMC did not appear to be dependent on 
initial bone mass, sex or age. There were no significant differences in 
changes of femoral bone mass (mean difference between both groups: 
0.3%, 95%-confidence interval: -25 to +26%). 
5 
0 
r 
-5 
Figure 2. 
% change 
from baseline 
• 
• • 
• 
• f 
no etidronate 
• 
• 
• 
• 
• 
• 
p=O.03 
etidronate 
Changes in vertebral Bone Mineral Content as percentage ch3l1ge from baseline after 1 year of prednisone 
treatment for patients with and without etidronate trCJ.tmcnt.llars indicate means with 95o/o-conlidence 
limits. 
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Table 3. Biochemical data (mean ± SEM) at entry and after 1 year of 
prednisone treatment. 
etidronate no etidronate 
(n=6) (n=6) 
Baseline I year Baseline 1 year 
Serum: 
Osteocalcine 3.0 ± 0.8 1.9 ± 0.5 2.3 ± 0.7 2.0 ± 0.5 
(N 1.8-6.6 flg/L) 
PICP 93 ± 9 70 ± 7 116 ± 9 103 ± 10 
(N 50-170 flg/L) 
PTH 31 ± 7 28 ± 5 21 ± 5 19 ± 4 
(N 10-55 ng/L) 
Calciulll i 2.3 ± 0.1 2.0 ± 0.3 2.3 ± 0.1 2.2 ± 0.1 
(N 2.20-2.7 nUllollL) 
25-(OH)D 51 ± 5 54 ± 3 49 ± 8 56 ± 5 
(N >30 nmollL) 
1,25-(OH),D 82 ± 17 92 ± 15 65 ± 8 59 ± 7 
(N 39-102 pmollL) 
Urine: 
D-pyrl creatinine 5.2 ± 0.8 4.3 ± 0.6 5.4 ± 1.8 4.9 ± 1.2 
(I1nlO11 l1ullol) 
Calciuln/ creatinine 0.24 ± 0.07 0.25 ± 0.08 0.21 ± 0.09 0.18 ± 0.04 
(mmoll mmol) 
t Corrected for SerUlll albumin 
N = normal range 
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No significant differences in changes of serum levels of 
osteocalcin, PICp, calcium, PTH or vitamin D metabolites, and urinary 
ratios of deoxypyridinoline/ creatinine and calcium/creatinine were 
noted between both treatment groups. In table 3 the values at baseline 
and after 12 months of treatment are presented. 
In the patients who were not treated with prednisone/ 
azathioprine, no significant differences were found between patients 
with (n=7) or without (n=5) etidronate, with respect to changes in 
BMC (lumbar spine: -1.1% ± 1.4 vs. -0.1% ± 2.6; femoral neck: -1.5% 
± 4.4 vs. -2.8 % ± 2.4, respectively) and biochemical parameters. 
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DISCUSSION 
This study indicates that cyclical etidronate may prevent steroid-
induced bone loss in PBC patients. The mean annual spinal bone loss 
has been reported to be 2% in a North-American PBC population (2), 
while a decrease of 1.3% was previously found in our PBC population 
(unpublished data). Corticosteroid-induced bone loss has been shown 
to be maximal during the first year of treatment (6,16,17), whereas the 
effect of long-term, low-dose treatment seems mild if present at all 
(7,18-20). Indeed, Mitchison et al. showed a doubled rate of bone loss 
during the first year oflow-dose glucocorticoid treatment in PBC 
patients (6), which is in agreement with our results. The lumbar bone 
loss of 0.8% in etidronate treated patients as compared to 3.5% in the 
untreated patients, suggests not only reduction but complete prevention 
of steroid-induced bone loss. Although the number of patients is 
relatively small and considering the precision error of DXA, the 
presented confidence limits and the magnitude of the observed 
difference plead in favour of a reliable finding. 
Corticosteroids are thought to exert their negative effect on bone 
status by both decreasing bone formation and increasing bone 
resorption. The metabolically active trabecular bone seems to be more 
prone to the steroid effects than cortical bone". This is in agreement 
with the accelerated bone loss observed at the site of the lumbar spine 
(mainly trabecular bone) but not in the femoral neck (mainly cortical 
bone).This may also explain the absence, as noted in accordance with 
others (10,12,22), of an explicit effect ofbisphosphonate treatment on 
femoral bone mass. Moreover, etidronate did not clearly affect bone 
mass in patients not treated with prednisone. This may not be surprising 
as etidronate is an antiresorptive drug, while decreased bone formation 
seems to be a major factor involved in PBC associated osteoporosis, 
particularly in patients with clinically less advanced disease (3,23), as 
included in our study. In regard of this, we found subnormal 
osteocalcine levels at entry in one third of the patients. However, 
possible type II errors cannot be excluded. 
Changes in biochemical markers varied considerably and no 
significant differences were found, although there appeared to be a 
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tendency towards a somewhat more pronounced inhibition of bone 
turnover in the etidronate treated patients. Cortico-steroids have been 
shown to reduce osteocalcine and PICP (15), and to affect calcium and 
PTH metabolism (17), but none of these effects could be established in 
our study. 
In agreement with a previous report from our center (18), bone 
status in our patients was not as problematic as found by other groups 
(24).Apart from differences in diet and life style, the relatively normal 
bone mass in our study may be due to the rather mild disease of our 
patients, which may be explained by the previous UDCA treatment 
(25), as well as by the exclusion of patients with very severe PBC 
(Child-Pugh Class B/C), who are considered unlikely to benefit from 
any medical treatment and should be considered for liver 
transplantation. Furthermore, our patient group included pre- and 
postmenopausal women as well as males. These patients, however, 
appear to be equally susceptible to the glucocorticoid effects on bone 
mass (21,26). 
Patients in the prednisone group who received etidronate had a 
lower mean APh than those without etidronate. APh levels, however, 
are not related to bone loss in chronic liver diseases (23,27). Other, 
more important markers of disease severity (histological stage, bilirubin 
levels), were comparable in both groups. UDCA treatment, which was 
used by all patients, does not seem to affect bone mass (28).As for 
azathioprine, given in combination with prednisone, we are not aware 
of any data regarding the effect of this drug on the bone status. 
Although this study is small and relatively short, we believe our 
findings are important, particularly in view of the recently reported 
disease modifYing effects of corticosteroid treatment in PBC (5-7,29). 
Etidronate appears to obviate the main drawback of this therapy, i.e. 
enhanced bone loss, and thus questions the prevailing ban on 
corticosteroids in PBe. Larger studies are needed to define the effect of 
etidronate, or other currently available bisphosphonates, on bone mass 
and fracture rate during more prolonged corticosteroid treatment. 
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1. INTRODUCTION 
Primary Biliary Cirrhosis (PBC) is a chronic, cholestatic auto-
immune liver disease of unknown origin characterized by a non-
suppurative destruction of interlobular and septal bile ducts (1).As a 
consequence of the bile duct destruction, endogenous bile salts will 
accumulate and hepatotoxic species, such as chenodeoA),cholic acid, 
will cause further liver damage (2,3). The majority of patients will 
develop biliary liver cirrhosis, which may eventually lead to death or 
liver transplantation. The natural course of the disease is variable and 
protracted and there is no proven method to predict, in an early phase 
of the disease, which patient will eventually have a fatal outcome. 
Once patients reach end stage disease, liver transplantation should 
be considered and PBC nowadays is one of the main indications for this 
operation (4). 
Medical treatment, directed at halting disease progression, has 
been largely disappointing (5-25). Table 1 provides a summary of 
randomized controlled trials, which have evaluated the efficacy of a 
wide variety of drugs in PBe. 
The experiences with ursodeoA),cholic acid, which was found to 
improve clinical, biochemical and histological features of the disease, 
revived the hope for an effective medical treatment for PBe. However, 
ursodeoA),cholic acid is thought to act mainly on the secondary, bile 
salt mediated damage; therefore the drug is unlikely to induce disease 
remissions or affect the natural course of the disease in a major way 
(26). A combination of ursodeoA),cholic acid with other drugs, 
preferably im1llunosuppressives, might be more effective (2,26-29). 
In the following we will discuss whether, during the last 5 years, 
UDCA has lived up to its promises. Furthermore the results of 
treatment regimens combining UDCA with other drugs, and future 
treatment options will be discussed. 
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Table 1. Controlled (single) drug trials in Primary Biliary Cirrhosis, other than ursodeoxycholic acid; 
effects on symptoms, liver tests, histology and survival (or need of liver transplantation). 
N.e. = not evaluable/evaluated; + ;;:;; improvement; ± = trend or not consistent; - = no improvement. 
The degree of intolerance has been estimated, based on the percentage of withdrawals/drop-outs in 
the treatment group as compared to the placebo group (++ = >10% and >2x the percentage in the 
placebo group;+ = >10% and >1.5x;- = :S10% or :S1.5x). 
Drug No. of Total no. Improvement Intolerance 
(references) studies patients symptoms liver functions histology survival 
Penicillarnine( 5-12) 8 740 ± ++ 
Colchicine (13-15) 3 181 ± ± + 
Chlorambucil (16) 1 24 n.e. + n.e. ++ 
Malotilate (17) 1 101 n.e. + + ++ 
Thalidomide (18) 1 18 n.e. ++ 
Methotrexate' (19) 1 87 + + n.e. n.e 
Prednisolone (20) 1 36 + + + n.e. 
Azathioprine (21) 1 45 + ± n.e. + 
(22) J2 248 + n.e n.e. + (5 yr: 41%. tl' 
Cyclosporin (23,24) 2 41 ± + n.e. + 
(25) J2 349 + + + (5 yr: 39%. t ITx) + 
1 = MTX vs. colchicine (ongoing): 
2 = presented more e:-. -plicitly :IS they are the only srudies in which surviv:J could be evaluated ... vith confidence; 
;\ = oftcr adjustment for unequal bilirubin levels at entry; 
!t/Tx = reduction in death/liver transplantation. 
2. UDCA 
A large quantity of clinical as well as basic research with regard to 
UDCA has been published during the last years. Apart from gallstone 
disease and PBC, UDCA has been administered with encouraging 
results in a wide variety of disorders, mostly with a cholestatic compo-
nent, such as primary sclerosing cholangitis, cystic fibrosis, hepatitis C, 
alcoholic liver disease, graft versus host disease and in the prevention of 
liver graft rejection (31). Here, we will focus on the use ofUDCA in 
PBe. 
2.1 UVrkillg IIIecitallislII 
The precise working mechanism of UDCA is still not completely 
understood, but several actions seem to be involved. Support has 
mainly been found for three concepts, i.e. modulation of the bile salt 
pool, direct hepatoprotection and immunomodulation (31). 
Hydrophobic bile salts can induce cell damage and cholestasis 
(32,33). The hydrophilic UDCA has a higher critical micellar concen-
tration and lower cell surface activity than endogenous hydrophobic 
bile acids. These properties result in a lower cell damaging capacity of 
UDCA (3,31,34). Therefore, enrichment of the bile acid pool with 
UDCA at the expense of hydrophobic bile acids is likely to reduce 
hepatic damage. Indeed, during UDCA administration UDCA 
conjugates form the largest proportion of bile salts in bile as well as in 
serum (3,35,36). UDCA treatment results in decreased reabsorption of 
endogenous bile acids from the gut (37-39); furthermore it enhances 
the elimination of bile salts, both by improving hepatocellular bile salt 
excretion (40) and by producing a bicarbonate-rich hypercholeresis, 
probably resulting from cholehepatic recycling of protonated UDCA 
(31). The latter mechanism, though, has only been documented in rats 
and seems of minor significance in humans (41-43). 
Several workers found the decrease in endogenous bile acids to be 
mainly at the expense of cholic acid, a relatively hydrophilic bile acid, 
while chenodeoAl'cholic acid, the main hydrophobic constituent of the 
bile acid pool, remained unaltered (37,44). In contrast to these reports 
Poupon et al. recently found UDCA to decrease the proportion of 
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chenodem,!,cholic acid in 150 patients participating in a placebo 
controlled trial with UDCA (45). Analysis of the biliary bile salt 
composition in 27 patients with PEC and PSC (36) showed a signifi-
cant decrease in the hydrophobicity index according to Heuman (46). 
So, although not all studies are univocal, a net shift towards hydrophili-
city in the bile acid pool seems likely. 
UDCA also seems to exert direct, hepatoprotective effects. It has 
been shown that UDCA reduces the cytolysis induced by other bile 
salts (31-33,43,47). In vitro studies showed that one potential cytopro-
tective mechanism may be the binding ofUDCA to cellular membra-
nes, thus decreasing membrane polarization and solubilization caused 
by hydrophobic bile salts (48,49).Whether the basolateralmembrane 
(48) or the canalicular membrane (49) is the major site of this 
cytoprotective action is still controversial. In support of the latter we 
found that biochemical improvement was related to the proportion of 
UDCA in bile but not in serum (36). Furthermore there is evidence 
that UDCA may also have hepatoprotective effects at the intracellular 
level; UDCA has been reported to reduce the impairment of 
mitochondrial function by hepatotoxic bile salts (50), to decrease 
intracellular concentrations of toxic endogenous bile salts by improving 
their hepatic excretion (40), and to modulate intracellular Ca'+ 
metabolism (51). 
Accumulating data indicate that UDCA also has immunomodula-
ting properties. The first indication was the fact that UDCA 
significantly reduced increased serum IgM levels in PEC (52). Then 
Calmus reported that UDCA reduces the aberrant HLA-l expression 
on hepatocytes (53). In PEC, aberrant hepatocytic HLA-l expression, 
as well as increased HLA-II expression on biliary epithelium, has been 
documented (54,55). HLA antigens are essential in the antigen 
recognition in immune processes. HLA-l antigens are required in the 
lysis of target cells by cytotoxic T-lymphocytes while T-helper cells can 
only recognize antigens in association with HLA-II (56). Increased 
HLA-I, but not HLA-II expression, may be secondary to cholestasis as 
it has also been found in extrahepatic obstruction (57).The recent 
reports that, in contrast to Calmus' findings, UDCA also reduces HLA-
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II expression on biliary epithelium, is therefore even more interesting 
(58,59). 
In vitro and in vivo studies have found UDCA to decrease the 
production of cytokines and inununoglobulins by mononuclear cells as 
well as lymphocyte proliferation (60,61). Normalisation of reduced 
levels of interleukin-2 and surf.1ce expression of dipeptidylpeptidase IV 
(CD26), an activation marker oflymphocytes, also suggest immunomo-
dulating mechanisms (62). 
Recently the role of intercellular adhesion molecule-l (ICAM-l) 
in immune reactions has been recognized. I CAM -1 and its 
lymphocytic ligand LFA-l (Lymphocyte Function-associated Antigen 
1) are important in lymphocyte migration towards and adhesion to 
target cells. In inflammatory circumstances, cytokines induce and 
enhance ICAM-l cell surface expression on lymphocytes and a variety 
of other cell types (63,64). In PBC, increased ICAM-l expression has 
been found on hepatocytes, and more specifically, biliary epithelium 
(65). 
Biologically active circulating soluble forms ofiCAM-l (sICAM-
1) have been identified, which can be shedded by activated lymphocy-
tes and, as has only recently been shown, by other cells such as 
endothelial cells (66) and hepatocytes (67), but apparently not biliary 
epithelium (68). slCAM-lleveis are velY high in PBC and correlate 
with stage and severity of disease (68,69).Although the exact origin 
and role of slCAM-l is still unknown, it has been suggested that 
slCAM-l levels may be useful in the investigation, diagnosis and 
monitoring of inflammatory and immune disorders, and several studies 
in a variety of diseases have supported this idea (70-75).We found that 
UDCA appears to reduce sl CAM -1 levels in PBC, and that further 
reduction can be achieved by combined prednisone/azathioprine 
therapy (76). In contrast, methotrexate did not reduce slCAM-l levels 
in PRC (77). 
The significance of these immunomodulating properties remains 
to be established, as they appear very heterogenous and it is not clear to 
what extent they are due to direct interference with the inunune 
system, or to reduction of inunune aberrations secondary to cholestasis 
(78). 
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2.2 Effects 011 liver filtlctioll tests, symptoms atld "ist%gy. 
Regarding PBC, a large number of controlled studies has now 
been published confirming the initial observations of Leuschner and 
co-workers (79) that UDCA improves liver function tests, particularly 
alkaline phosphatase, gamma-glutamyl transferase and transaminases (52, 
80-88; table 2). UDCA also seems to lower or stabilize serum bilirubin. 
Furthermore serum IgM, which is thought to reflect immune reactivity, 
also decreases during UDCA treatment. 
Poupon in 1991 (52) claimed an effect ofUDCA on pruritus, 
however this finding f.1iled to reach significance. The results of other 
trials also indicate at most mild improvement of pruritus by UDCA as 
compared to placebo (81,85-88). Only Hadzyannis et al. (82) found 
significantly greater ameliorations of pruritus in the UDCA treated 
patients. Of the six studies reporting on f.1tigue, again, Hadzyannis was 
the only one who noted a f.wourable effect ofUDCA. 
Six groups reported data on histology (52,80,82,86-88). None of 
them could report a convincing effect on fibrosis and histological 
progression. Four groups looked at a variety of histological features. 
One did not find any difference between groups (82), three found 
differences in favour ofUDCA (52,80,88), although in one these did 
not reach significance (80). Differences were noted for bile duct paucity 
and proliferation, degree of portal and lobular inflanmlation and piece 
tneal necrosis. 
Some authors have suggested lower or no efficacy ofUDCA in 
patients with cirrhosis (82,89).We found that, in patients with Child-
Pugh Class A cirrhosis, UDCA treatment induces a clinical and 
biochemical response comparable to that in non-cirrhotic patients. 
Therefore, based on the available data, UDCA should not be denied to 
these patients (90). 
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Table 2. Controlled trials (published as full article) with ursodeoxycholic acid in Primary Biliary Cirrhosis: 
effects on sym.ptoms, liver tests, histology, disease progression and survival/need of liver transplantation 
(n.e. = not evaluable/ evaluated;+ = improvement; ± = trend or not consistent;- = no improvement) 
Author Dose No. of Follow Symptoms Liver Histology Signs of Survival! 
year (ref) patients up functions injIammationlfibrosis progressionl liverTx 
(mg/day) (n~ ) (months) [bilirubin] 
Leuschner 10/kg 20 9 ± + [n.e.] ± /- n.e. D.e. 
1989 (80) 
Oka 600 45 6 + [-] D.e I n.e. ll.e. 
1990 (81) 
Hadzyannis 12-15/kg 50 mean 29 + + [±] -/- -/-
1991 (82) 
POUPOD 13-15/kg 146 48' ± + [+] + /- + -/+ 
- 199111994 .... 
00 (52.83) 
Hwang 600 12 3' ± + [+] D.e. / n.e. n.e. ll.e. 
1993 (84) 
Battezzati 500 88 6 + [+] D.e. / n.e. rr.e. 
1993 (85) 
Turner 10/kg 46 24 + [+] - / ± -/-
1994 (86) 
Lindor 13-15/kg 180 mean 24 + [+] D.e. /- + -/-
1994 (87) 
Heathcote 14/kg 222 24 + [+] +/- -/-
1994 (88) 
signs of progression: hepatic decompensation e.g. ascites. variceal bleeding. encephalopathy 
last 2 yem uncontrolled 
cross-over design with 3 month-periods 
2.3 Toleratlce alld adverse iffects 
UDCA is generally considered to be a very safe drug with 
virtually no side effects. In the published controlled trials (52,80-88), 
5% of UDCA treated patients reported adverse effects, mostly 
(transient) diarrhea or worsening of pruritus. Three percent of these 
patients discontinued treatment. Moreover, comparable percentages of 
side effects and withdrawals were noted in the placebo treated patients 
(4 and 3% respectively). 
However, some workers observed acceleration of the disease in 
cirrhotic PBC patients (91,92). Review of these reports indicate that 
most of these patients had clinically advanced disease. In contrast, 
UDCA appears safe in Child-Pugh class A patients (90). We believe 
UDCA is contraindicated in patients with decompensated cirrhosis 
(Child-Pugh Class B or C) (93), because of the improbability of 
beneficial effects and possible deterioration. Liver transplantation should 
be the primary consideration in these patients. 
2.4. Effect 011 disease progressioll 
Several relatively large placebo-controlled trials (83,87,88) have 
indicated that treatment L1i1ures (endpoints such as rise in bilirubin, 
development of ascites, variceal bleeding, progression to cirrhosis, death 
or liver transplantation) occur about twice as often in placebo treated 
patients than in UDCA treated patients (figure 1). These findings were 
confirmed by a recent meta-analysis ofUDCA treatment in PBC (94). 
However, a clear improvement in survival and reduction in need for 
transplantation could not be substantiated yet. Poupon noted a signifi-
cant reduction in the need ofliver transplantation in those patients who 
had received 4 years of UDCA as compared to those who had received 
placebo dnring the initial 2 years followed by 2 years ofUDCA treat-
ment (83).These results shonld be interpreted cautiously as the decision 
to perform liver transplantation is rather subjective and the trial was not 
double blind at that stage. 
It should be stressed that all of these studies had relatively short 
follow-up periods (up to 4 years) and lacked the power to assess effects 
on survival. Hopefully, the pending meta-analysis of the raw data of 
four large controlled studies (83,87,88,95) will shed more light in the dark. 
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2.5. Alternative assesst1/ettt of treattllent @cacy 
The golden standards for the assessment of therapeutic efficacy 
are improvement of survival (and, in case of PBC, reduction of need for 
liver transplantation) and quality oflife. The relative rarity of PBC and 
its unpredictable and protracted natural course (often over 10-20 years) 
limit the feasibility to assess survival in controlled trials. Therefore 
alternative endpoints or markers indicative of treatment efficacy are 
warranted to identifY potentially effective treatments. However, positive 
results still require subsequent confirmation by long term controlled 
studies (96,97). 
The most important prognostic markers currently in use are 
bilirubin, albumin and clotting parameters, or scores and indexes 
containing -more or less- all of these variables (22,93,98-100). 
Recently published models offer the possibility to adjust the estimated 
prognosis during the course of the disease (99,100). However, these 
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models have been developed in untreated patients and whether they are 
also applicable to treated patients is not clear yet. UDCA may lower 
serum bilirubin, the major component of all models, by increasing its 
biliary excretion; therefore, the prognostic value of these models may 
be limited in patients taking UDCA (97). Despite these considerations, 
these models seem useful in the difficult process of timing of liver 
transplantation. 
Patients are likely to benefit from medical treatment only during 
the early phase of the disease. The above mentioned prognostic indica-
tors only become disturbed in the later stages of the disease. Therefore, 
other indicators of efficacy of medical treatments are required. 
One alternative may be to study the potential of a treatment to 
induce complete disease remission (27). This is a well-established con-
cept in hematological diseases such as leukemia and malignant 
lymphomas, and in autoimmunological disorders like chronic autoim-
mune hepatitis (lOl).When using criteria for remission, as proposed by 
Beukers and Schalm (27), less than 5% ofPBC patients will achieve a 
complete remission during UDCA treatment (102). However, these 
strict criteria are arbitrary and await further validation. 
Markers of fibrogenesis, like procollagen-Ill-propeptide (P-III-P) 
and hyaluronic acid, may be appropiate alternatives (103). Particularly 
P-JII-P has been reported by several independent groups to have 
prognostic significance with regard to survival and development of 
complications ofliver disease (104-106). Measurements ofP-III-P and 
hyaluronic acid levels in one uncontrolled study showed no effect of 
UDCA treatment (89). 
The use of histological features, like degree of fibrosis, as 
surrogate parameters is hampered by sampling error and the invasiveness 
of the procedure. Moreover, improvements in bile ductular and inflam-
matory aspects, as reported for UDCA, lack prognostic significance. 
Dynamic liver function tests (e.g. bromosulpthalein clearance test, 
aminopyrine breath test, galactose excretion test) may become impor-
tant prognostic parameters, but at this moment their significance in 
patients with non-advanced disease is unclear (97). 
In the future, other parameters such as sICAM-lmay also show 
to be suitable for monitoring treatment effects in PBe. 
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2.6. How to administer UDCA? 
The optimal way ofUDCA administration has not been 
completely elucidated yet; there is a large variation in the doses used by 
different groups (table 2).Although one short-term, cross-over study in 
a small group ofPBC patients indicated no extra benefit of750 mg 
UDCA over 500 mg per day (107), good dose response studies in 
cholestatic disorders have not been performed and the dosage of 10-15 
mg/kg as is being used now may be suboptimal. For example in cystic 
fibrosis the optimal dosage seems to be 20 mg/kg/d (108). 
Furthermore, it was recently suggested by some authors, that a 
divided daily dose should be applied, since in experiments with a single 
gift of UDCA the proportion absorbed in the ileum decreased with 
higher doses (109).We found no difference between a divided dose and 
a single bedtime dose with regard to biochemical improvements or 
biliary UDCA enrichment during chronic UDCA administration (36); 
therefore, in view of the better patient compliance, a single bedtime 
dose, taken with a small snack to improve absorption, appears to be 
preferable. 
Further studies to establish the optimal way ofUDCA admini-
stration may lead to an increased therapeutic efficacy. 
3 COMBINATION THERAPY WITH UDCA 
In view of the limited effects of single drug therapy in PBC, it 
has been suggested to turn to the evaluation of combinations of drugs 
with at least partial efficacy in the treatment of PBC (27-29) 
Next to UDCA a number of drugs, e.g. chlorambucil, cyclos-
porine, prednisone, azathioprine, methotrexate, colchicine and 
malotilate have been shown to have beneficial effects in PBC as 
evidenced by (at least) amelioration of liver function abnormalities. The 
toxicity of the immunosuppressive drugs chlorambucil (bone marrow 
depression) and cyclosporine (nefrotoxicity) seems to outweigh the 
beneficial effects and these agents are therefore considered less suitable 
options (16,23-25,110). Another drug with immunosuppressive 
properties, thalidomide, has been tried in PBC but showed no favoura-
152 
ble effects on symptoms, liver tests and histology (18). 
Recently, a placebo-controlled study evaluating malotilate (17), a 
drug with presumed hepatoprotective and antifibrotic properties, 
documented moderate improvements of laboratory parameters and 
histological inflammation. Adverse effects were relatively frequent and 
one patient developed a serious toxic hepatitis. Moreover, malotilate is. 
not commercially available outside Japan. 
Some authors have already reported data on combinations of 
UDCA with methotrexate (114-116), colchicine (117-121) and 
prednisone (26)(table 3). Methotrexate may be effective in early stage 
PBC as has been suggested by several small studies (111-113). Kaplan 
evaluated the combination of methotrexate (15 mg weekly) with 
UDCA in 14 PBC patients and found additional effects on biochemist-
ry, £1tigue and itching (115). Buscher et a!. (116) also studied the effects 
of methotrexate added to previous treatment with UDCA.Alkaline 
phosphatase improved in 6 of the 8 patients. As reported by others, 
transaminases initially rose but subsequently decreased. Symptoms also 
improved after initial deterioration. However, methotrexate may have 
severe adverse effects. PBC patients seem to be particularly susceptible 
to interstitial pneumonitis and this has been reported in up to 14% of 
treated patients (122). 
Colchicine, a drug with anti-inflammatory and antifibrotic 
properties, is well tolerated and has been shown to improve 
biochemistry in PBC. Moreover some authors have previously 
suggested slowing of progression (13,15), which was not supported by a 
study with long term follow-up of colchicine treated patients (123). In 
contrast to one uncontrolled study (121), four placebo-controlled trials 
did not show clear additional effects of colchicine to UDCA with 
respect to symptoms and biochemistry (117-120). 
Scarce data in mostly advanced PBC patients indicated that major 
improvements could not be induced by corticosteroid treatment (124-
126). It has even been suggested that response to prednisone is an 
important determinator in the differential diagnosis ofPBC and auto-
inmlUne hepatitis (127). Moreover prednisone has long been considered 
contraindicated in PBC, mainly because of its negative effects on the 
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bone status (128). The partial effect of inllllunosuppression in PBC, 
may be related to the role of accumulated toxic bile salts in liver 
damage, which is not obviated by immunosuppression. With respect to 
bone mass, more recent data have shown that, although bone loss is 
enhanced during the first year of treatment (129-131), negative effects 
on bone during long term treatment with low dose corticosteroids 
seem to be absent or mild (19,132-134). Furthermore, steroid induced 
bone loss in PBC appears to be prevented by cyclical etidronate, an 
anti-bone resorptive drug belonging to the class ofbisphosphonates 
(135). Similar observations with bisphosphonates have been made in 
other steroid treated disorders (136-138). 
Another way to minimize adverse effects while maintaining the 
inllllunosuppressive potential is to combine low doses of prednisone 
and azathioprine. Azathioprine has immunosuppressive properties and 
has been shown to improve survival in PBC, albeit to a minor extent 
(21). 
A combination of prednisone (initially 30 mg/ d reduced in 2 
months to 10 mg/d maintenance dose), and azathioprine (50 mg/d) 
was added to UDCA in a placebo-controlled study in 36 patients who 
had not achieved remission with UDCA alone (139). Pruritus, alkaline 
phosphatase,ASAT, IgM, P-III-P, soluble ICAM-1 as well as histolo-
gical inflammation improved significantly on top of the previous effects 
ofUDCA alone. As mentioned above, steroid enhanced bone loss 
seemed to be prevented with cyclical etidronate. Weight gain was the 
major adverse effect. In 3 prednisone treated patients cosmetic changes 
were considered problematic and were accompanied by increases in 
blood pressure; two patients in the placebo group were withdrawn 
because they became in need ofliver transplantation while in the 
treatment group 3 patients withdrew within one month (2 general 
malaise, 1 spontaneous bacterial peritonitis). In a chronic disease like 
PBC, a high induction dose may not be necessary and in future studies 
the risk of adverse events may be reduced by abolishing this high dose. 
Based on the short term benefit/risk ratio larger, long term controlled 
studies with this regimen, under bisphosphonate protection, seem 
indicated to assess its effect on disease progression (139). 
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Table 3. Studies evaluating the addition of other agents to UDCA in PBC 
Agents Author Year 
Methotrexate Kaplan 1992 
Buscher 1993 
Colchicine Raedsch 1992 
Podda 1992 
Poupon 1994 
Goddard 1994 
Shibata 1992 
Prednisone Wolfhagen 1995 
+ 
Azathioprine 
Reference Type of 
study 
115 Open 
116 Open 
117 RCT 
118(A) RCT 
119 (A) RCT 
120(A) RCT 
121 Open 
139 RCT 
ReT == randomized pbcebo-controlled trial 
(Al == published in abstr.lct form 
1 ongoing trial 
1 bromsulphatelein clearance improved in colchicine group (p<O.Ol) 
:; four r..mdomized groups; UDCA. colchicine. UDCA +colchicine, pbcebo; 
lower decre:lSe of albumine in UDCA+colchicine treated group (p=O.02) 
No of Follow-up Additional beneficial effects to UDCA 
patients (months) ~ymptoms,Qiochemistry,histology) 
14 mean 17 suggestive (s,b) 
8 6 suggestive (s,b) 
22 12 no (s,b,h) 
88 ,I no (s,b) 
74 24 no (s,b,hf 
57 mean 15 no (S,b)3 
12 24 suggestive (b) 
36 12 yes (s,b,h) 
4 FUTURE TREATMENT OPTIONS 
To establish a specific, curative medical therapy for PBC, increased 
knowledge on the etiology and pathophysiology of the disease and 
identification of the antigens involved in the primary immune attack is 
needed. However, as long as this knowledge is not available, therapy 
should aim at optimal suppression of disease activity and halting 
progression, preferably in an early stage of the disease. Such treatments 
should have a low toxicity profile, like UDCA. 
In this respect, we believe that the long term evaluation of the 
combination ofUDCA with corticosteroids and azathioprine under 
bisphosphonate protection is promising. It remains to be established 
whether it is preferable to replace prednisone by newly synthesized 
corticosteroids with (presumed) relatively bone sparing properties (e.g. 
deflazacort) in PBC (140-142). 
Evaluation of other drug combinations could be worthwhile too. 
Methotrexate is still an option, but the problem of the high incidence 
of interstitial pneumonitis should be adressed. Combination with 
cyclosporin-like inmlUnosuppressives such as FK 506 or new 
antifibrotic drugs (HOE 077) may also be attractive for future research. 
Advances in molecular biology may disclose new potential 
treatment options aiming at specific factors involved in inflammatory, 
immunological and fibrogenetic processes like cytokines and adhesion 
molecules (143-151). 
Experimental research in animals has indicated that autoimmune 
disorders may be cured by bone marrow transplantation (152). Several 
cases of remissions of autoimmune diseases (psoriasis, arthritis, 
ulcerative colitis) following bone marrow transplantation for a coexis-
ting disorder, have been reported (153-155). 
To obtain an optimal benefit/risk ratio, treatment should 
preferably be instituted in an early stage of the disease, in particular 
before cirrhosis has developed. Furthermore a method to predict, in an 
early stage, whether a patient will show progressive disease would be 
very valuable, especially when considering more invasive interventions 
such as bone marrow transplantation. The development of such models 
is therefore of utmost importance. 
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5 CONCLUSION 
During the last five years there has been substantial progress in the 
medical treatment of PBe. UDCA tends to reduce symptoms, 
improves liver tests and histological features and seems to slow down 
disease progression, albeit to a modest extent. Moreover, UDCA is a 
very safe drug. Despite its limitations, these properties justifY the use of 
UDCA as current standard treatment in non-advanced PBe. 
Furthermore, in contrast with previous believe, prednisone, when 
given in combination with azathioprine and UDCA, has been shown 
to have clear beneficial effects in PBC while enhanced bone loss 
appears to be manageable by the use of bisphosphonates. We believe 
that our current results justifY the initiation oflong term studies to 
evaluate this triple treatment regimen with UDCA, prednisone and 
azathioprine. 
Further research regarding the etiology and pathophysiology of 
the disease is required to enable the eventual development of a curative 
treatment for PBC, other than liver transplantation. 
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SUMMARY 
The studies presented in this thesis aimed at exploring the benefits 
and risks of the treatment of primary biliary cirrhosis (PBC) with 
ursodeoxycholic acid as monotherapy, and in combination with 
prednisone and azathioprine. These studies were performed in the 
context of a Dutch multicenter project which was initiated in 1990. 
Chapter I 
This chapter presents a general introduction regarding the clinical 
picture and pathophysiology of this enigmatic disease, with a more 
detailed review of the therapeutic state of the art in 1990. While liver 
transplantation had become a life saving therapy for patients with end-
stage PBC, efforts with a large variety of drugs, to discover an effective 
medical therapy had been in vain.At that time the first promising 
controlled trials on ursodem.'ycholic acid were published. Based on the 
supposed pathophysiology of PBC and the action mechanisms of 
UDCA, the rationale of combining UDCA with immunosuppressive 
drugs is elucidated. Moreover, the aims of this thesis are described in 
this chapter. 
Chapter II 
Here we aimed at assessing how many PBC patients would 
achieve a disease remission during a 1-year course ofUDCA (ca. 10 
mg/kg/day). In doing so, incompletely responding patients, who were 
considered potential candidates for further trials, could be identified. In 
spite of the observed beneficial effects on symptoms and liver tests, less 
than 5% of the 110 treated patients achieved a complete remission 
according to our criteria. 
Chapter III 
Several authors had found the response to UDCA treatment to be 
minor or absent in small, heterogenous groups ofPBC patients with 
cirrhosis. Moreover, UDCA had been reported to induce disease 
deterioration in cirrhotic PBC patients. In this chapter we compared 
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the tolerance and response to UDCA in PBC patients with Child Pugh 
Class A cirrhosis (n=20) and patients without cirrhosis (n=39). No 
differences in response were found between both groups and none of 
the cirrhotic patients showed clear worsening of the disease. 
Chapter IV 
It had been advocated that UDCA should be given in multiple 
small doses during the day rather than in one single gift. We compared 
biochemical response and biliary UDCA enrichment in 27 patients 
with cholestatic liver diseases (PBC, psq, who were randomized to 
receive UDCA either according to a divided dose or a single dose 
regimen. UDCA enrichment correlated with biochemical improve-
ments of alkaline phosphatase, transaminases and y-glutamine transfera-
se. There were no differences in biochemical response or biliary enrich-
ment between both treatment regimens. 
Chapter V 
This retrospective study in 7 PBC patients rendered the first data 
regarding the synergistic effects ofUDCA and inm1llnosuppressive 
treatment on symptoms and liver tests. These findings led to the the 
initiation of the studies described in the following chapters. 
Chapter VI 
Here an interim-analysis is reported of 36 patients participating in 
a I-year, double-blind, placebo-controlled trial with prednisone and 
azathioprine, given in addition to UDCA. In the treatment group, but 
not in the placebo group, clear and significant improvements in itching, 
markers of liver cell necrosis, cholestasis, fibrogenesis and inunune 
activity, as well as in inflammatory features on liver biopsy were noted. 
These effects were obtained on top of ameliorations previously induced 
by UDCA monotherapy. In the treatment group 3 patients were 
withdrawn from treatment because of adverse events compared to 2 
patients in the placebo group, who were withdrawn following disease 
progression and eventual referral for liver transplantation. Corticoste-
roid induced bone loss seemed to be prevented by the use of bisphos-
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phonates (see chapter 8). The short term benefit/risk ratio appeared to 
justifY further long term trials with this triple treatment regimen. 
Chapter VII 
Soluble Intercellular Adhesion Molecule-l (sICAM-l) in serum 
has been proposed as a marker of disease activity in immune diseases, 
such as PBe.We studied sICAM-l levels in 24 patients before and 
during UDCA therapy and during additional prednisone/azathioprine 
or placebo treatment. sICAM-l concentrations at entry correlated with 
histological stage, bilirubin and transaminases, but not with a marker of 
lymphocyte activation, i.e. soluble Interleukin-2 receptor. This suggests 
a local (hepatic) rather than a lymphocytic origin ofsICAM-l in PBe. 
UDCA diminished sICAM-concentrations by a median of 20%, indica-
ting an inullunomodulatory effect of this drug. Further decreases 
(median 25%) were achieved by prednisone and azathioprine but not by 
placebo. 
Chapter VIII 
To assess whether cyclical etidronate could reduce corticosteroid 
induced bone loss in PBC, 24 patients participating in the trial 
described in chapter 6 were randomized to receive either cyclical 
etidronate + calcium or calcium alone. Bone Mineral Content in the 
lumbar spine and proximal femur were monitored using Dual Energy 
X-ray Absorptiometry. In the prednisone treated patients etidronate 
appeared to prevent the enhancement of vertebral bone loss by 
corticosteroid treatment. No differences in bone loss between placebo 
treated patients with or without etidronate were noted. Femoral bone 
loss was comparable in all groups. These data indicate that the main 
drawback of corticosteroid therapy in PBC, increased bone loss, can be 
obviated by bisphosphonates. 
Chapter IX 
In this chapter the advances regarding the treatment of PBC 
during the last 5 years and future therapeutic options are discussed. 
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SAMENVATTING 
In dit proefschrift worden een aantal studies beschreven met 
betrekking tot de effecten en bijwerkingen van behandeling van pri-
maire biliaire cirrose (PBC) patienten met ursodeoA"c1lOlzuur (UDCA) 
alleen, alswel in combinatie met prednison en azathioprine. Deze 
studies werden uitgevoerd binnen een Nederlands multicentrisch 
projekt dat werd gestart in 1990. 
Hoofdstllh I 
Dit hoofdstuk geeft een algelllene introductie met betrekking tot 
de kliniek en patho£Ysiologie van deze raadselachtige ziekte, met een 
meer gedetailleerd overzicht van de stand van zaken rond de behande-
ling van PBC anno 1990. De levertransplantatie had zich ontwikkeld 
tot een effectieve, levensverlengende ingreep voor patienten in het 
eind-stadium van de ziekte. Daarentegen waren alle pogingen om een 
effectieve medicamenteuze behandeling voor PBC te vinden tevergeefs 
gebleken. Rond die tijd, echter, kwamen de eerste veelbelovende data 
van gecontroleerde trials met UDCA beschikbaar. Op basis van de 
veronderstelde patho£Ysiologie van PBC en de werkingsmechanismen 
van UDCA wordt de rationale van gecombineerde behandeling van 
UDCA met immunosuppressie toegelicht. Tevens worden de doelen 
van dit proefschrift beschreven. 
Hoofdstllh II 
In deze studie wilden wij bepalen hoeveel patienten met PBC in 
remissie zouden komen gedurende 1 jaar UDCA behandeling (ca. 10 
mg/kg/dag). Op deze manier konden tevens die patienten die niet of 
slechts gedeeltelijk op UDCA respondeerden worden ge1dentificeerd. 
Deze zouden dan in aanmerking kunnen komen voor verdere behande-
lingsstudies. Ondanks de duidelijk positieve effecten op klachten en 
levertesten, voldeed na 1 jaar mindel' dan 5% van de patienten aan onze 
criteria voor complete ziekte remissie. 
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Hoofds/llk III 
Verschillcnde onderzoekers hadden geen of slechts een geringc 
respons op UDCA gevonden in kleine aantallen patienten met PBC 
stadium IV (cirrose). Ook was door enkele auteurs verslechtering van 
de ziekte gerapporteerd, die zij weten aan het gebruik van UDCA. Wij 
vergeleken de tolerantie van, en de respons op UDCA in PBC patien-
ten met gccompenseerde (Child-Pugh Class A) cirrose (n=20) en 
patienten zonder cirrose (n=39).Wij vonden geen verschillen m.b.t. 
respons tussen beide groepen. In geen van de cirrose patienten trad een 
duidelijke verslechtering van de ziekte op. 
HooJds/llk IV 
Men heeft geopperd dat UDCA betel' kan worden toegediend in 
over de dag verdeelde giften dan in een enkelvoudige dosis. Wij verge-
leken de biochemische respons en biliaire UDCA verrijking in 27 
patienten met cholestatische leverziekten (PBC, PSC), die gedurende 3 
maanden werden gerandomizeerd naar een multi pel of enkelvoudig 
UDCA doseringsschema. Dc biliaire UDCA verrijking correleerde met 
de afuames van alkalisch fosfatase, y-glutamine transferase en transami-
nases. Er waren geen verschillen in biochemische respons en biliaire 
UDCA verrijking. 
HooJds/llk V 
Deze retrospectieve stu die in 7 PBC patienten toonde voor het 
eerst synergistische effecten van UDCA en immunosuppressieve behan-
deling. Deze bevindingen leidden tot de start van de studies zoals 
beschreven in de volgende hoofdstukken. 
HooJds/llk VI 
Hierin wordt een interim analyse gerapporteerd van 36 patienten, 
deelnemend aan een 1 jaar durende, dubbelblinde, placebo-gecon-
troleerde stu die met prednison en azathioprine, toegevoegd aan eerdere 
UDCA behandeling. In de behandelingsgroep, maar niet in de 
placebo-groep, werden duidelijke, significante verbeteringen in jeuk, 
serologische testen voor levercelverval, cholestase, fibrogenese en 
imll1uunactiviteit, en in ontstekingsverschijnselen op het leverbiopt 
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gevonden. Deze effecten werden bereikt bovenop de verbetcringen 
verkregen door de voorafgaande behandeling met UDCA aileen. In de 
behandelingsgroep stopten 3 patienten met de behandeling vanwege 
bijwerkingen, terwijl in de placebo groep 2 patienten stopten wegens 
ziekteprogressie en, niteindclijk, verwijzing voor levertransplantatie. 
Toename van botverlies door prednison leek te worden voorkomen met 
behulp van cyclische behandeling met het bisphosphonaat etidronaat 
(zie hoofdstuk 8). Deze korte termijn bevindingen lijken de opzet en 
uitvoer van verdere langdurige studies met dit behandelingsregimen te 
rechtvaardigen. 
Hoofdstllk VII 
Men heeft geopperd dat oplosbare vonnen van het Intercellulaire 
Adhesie Molecuul-l (sICAM-l) een parameter voor ziekte activiteit bij 
inm1Unologische aandoeningen, zoals PEC, zou kunnen zijn. Wij 
onderzochten sICAM-l concentraties in 24 patienten voor en gedu-
rende UDCA therapie en gedurende additionele behandeling met 
prednison/azathioprine of placebo. sICAM-l concentraties voor start 
correleerden met histologisch stadium, bilirubine en transaminase 
spiegels, maar niet met de concentratie van oplosbare Interleukine-2 
receptoren, een parameter voor lymfocyt-activatie. Dit wijst op cen 
lokale (hepatische) en niet zozeer een lymfocytaire oorsprong van 
sICAM-l bij PEe. UDCA verlaagde de sICAM-l concentraties met 
een mediaan van 20%, hetgcen een immunomodulerend effect van 
UDCA suggereert.Verdere verlaging van sICAM-l spiegels (mediaan 
25%) werd bereikt met prednison en azathioprine maar niet met 
placebo. 
Hoofdstllk VIII 
Om te bepalen of cyclisch etidronaat het corticosteroId geIndu-
ceerde botverlies bij PEC zou kunnen verminderen, werden 24 patien-
ten deelnemend aan de studie, zoals beschreven in hoofdstuk 6, 
gerandomizeerd naar behandeling met etidronaat+calcium (in cycli van 
3 maanden) of calcium aileen. De mineraalinhoud van de wervelkolom 
en proximale femur werd vervolgd met behulp van Dual Energy X-ray 
Absorptiometry. In de groep patienten die werd behandeld met predni-
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son/azathioprine bleek behandeling met etidronaat het corticostcroid-
gdnduceerd botverlies in de werve!kololl1 te voorkomen. Er werden 
geen verschillen in botverlies gevonden tussen patienten in de placebo 
groep met of zonder etidronaat. Het botverlies in de heup was 
verge!ijkbaar in aile groepen. Deze gegevens suggereren dat het voor-
naamste nadee! van corticosteroidenbehandeling bij PBC, namelijk 
toegenomen botverlies, ondervangen kan worden met behulp van 
bisphosphonaten. 
Hoojds/llk IX 
In dit hoofdstuk worden de vorderingen gedurende de laatste vijf 
jaar met betrekking tot de behandeling van PBC besproken. Tevens 
wordt ingegaan op toekomstige behandelingsmogelijkheden. 
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DANKWOORD 
Het in dit proefSchrift beschreven onderzoek werd niet aileen 
verricht in het Academisch Ziekenhuis Rotterdam, maar in vele klinie-
ken - academisch en perifeer, groot en klein - in heel Nederland. Bij 
zeldzame ziekten zoals PBe telt e1ke patient en aileen samenwerking 
kan leiden tot goed en zinvol onderzoek. Ik wil dan ook graag aile 
artsen en patienten bedanken die deelnamen en -nemen aan het Multi-
centrische PBe Project. Ik hoop dat allen enthousiast zullen blijven 
participeren aan dit en soortgelijke projecten. Ook financiele support is 
onontbeerlijk en ik ben de diverse sponsors dan ook zeer erkentclijk 
voor hun steun. Met name Zambon Nederland BV en in het bijzon-
der Gerrit Paarlberg wil ik bedanken voor de organisatorische diensten 
met be trekking tot de N ederlandse Multicenter PBe studie. 
Ben aantalmensen zou ik in het bijzonder willen noemen. Op de 
eerste plaats Henk van Ellmen, niet aileen mijn bezielde begeleider, 
maar eellwige stelln en toeverlaat; altijd had hij tijd voor mij, vaak ten 
koste van zijn eigen dl'llkke programma; zijn optimisme en enthou-
siasme vormden regelmatig een goed tegenwicht voor mijn pessimisti-
sche buien. Henk, ik zal ons sigaartje en ons borreltje (na zessen, hoor!) 
l111ssen. 
Mijn promotor Prof. dr. SoIko Schalm die mij de mogelijkheid 
heeft geboden om dit proefSchrift tot stand te brengen, zij het af en toe 
met bloed, zweet en tranen. Dank ook voor de duwtjes (en soms een 
f1inke zet?) in de juiste richting. 
Ook mijn Utrechtse promotor, Prof. dr. Gerard van Berge Hene-
gouwen, ben ik zeer erkentelijk voor zijn enthousiasme, zijn belangstel-
ling en met name ook zijn snelle beoordeling van de vele protocol-
voorstellen en manuscripten. 
Dan wil ik mijn dank betuigen aan twee personen, die mijns 
inziens het prototype van de ware wetenschapper personifieren, gezien 
de Iichtelijk wanordelijke toestand op hun werkkamer (overigens sterk 
gelijkend op de chaos op mijn eigen kamer). Ten eerste Ir. Wim Hop, 
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van de afdeling biostatistiek van de Erasmus Universiteit, bij wie ik 
onder het genot van een lekker "shaggie" menig statistisch wonder 
geboren zag worden. Ten tweede Prof. dr. Fiebo ten Kate, patholoog-
antoom, met wie ik, onder het genot van een lekker bakje koffie in het 
AMC of bij hem thuis, vele uren biopten heb zitten bekijken, tot de 
hoofdpijn er op volgde. Hier wil ik ook Paul Dillenburg noemen, die 
in het AMC onze biopten ordende en mee beoordeelde. 
De dames van het trial bureau - waarvan ik er enkele letterlijk heb 
"versleten" blijkens het tempo waarin zij onze afdeling verlieten zodra 
zij met mij moesten werken - verdienen ook een woord van dank: 
Marja, Annelies, Kim, en verdeI' Willeke, Juliette, Marjan, Carin, Ellis, 
Nicole, en natuurlijk ook Stanny de Roode, met wie ik, samen met 
Henk, een jaar lang het berghok van de afdeling heb mogen delen. Zij 
stak mij vaak een hart onder de riem en hield me daarnaast op de 
hoogte van aile afdelingsroddels en -nieuwtjes. 
Ook de dames van de polikliniek heb ik waarschijnlijk meer dan 
eens tot wanhoop gebracht, o.a. met mijn vroege spreekllur, waar best 
(heel graag, dus) van afgeweken mocht worden. Frequent waren ook 
hun (vaak succesvolle) razzia's op onze kamer, met als doel het opspo-
ren van missende statussen. 
AIle medewerkers van de Balansafdeling (0 sorry, Clinical Re-
search Unit) wil ik eveneens hartelijk bedanken voor de wijze waarop 
zij hebben geholpen om de trials goed te laten verlopen, ondanks het 
feit dat patienten nog wei eens totaal onverwacht op de Unit versche-
nen. 
Jan Boot, bedankt voor je altijd snelle reactie op elk wanhopig 
telefoontie dat van achter mijn computer vandaan kwam. 
Jopie Hensen, die de botmassametingen verrichtte wi! ik een 
pillim geven voor de uiterst flexibele wijze waarop zij toch e1ke keel' 
weer op korte termijn een plaatsje wist te creeeren voor mijn trial-
patienten, ondanks haar overvolle agenda. Ook Cock BUllrman en 
Gert-Jan van de Bemd (laboratoriu1l1 Inwendige Geneeskllnde III) wil 
ik danken voor het snelle en adequate bepalen van de diverse bot-
ombollw markers. 
Dr. Huib Pols, bedank ik voor zijn inbreng en begeleiding m.b.t. 
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de "botstudie" en Ingrid de Graaf en Lidwien Hanff, apothekers in het 
Academisch Ziekenhuis Rotterdam voor de prettige samenwerking. 
Monica wil ik even speciaal noemen, voor al de 1l10eite die zij 
zich heeft getroost om voor mij biopten en verslagen uit de diepste 
spelonken van het pathologie archief te voorschijn te halen. 
Prof. dr. ET. Bosman, Prof. dr.].e. Birkenhager en Prof. ].H.P. 
Wilson dank ik heel hartelijk voor hun snelle beoordeling van het 
manuscript en hun bereidheid om zich tijdens de Paasdagen van 1995 
te verpozen met zo'n 250 bladzijden PBe. 
I would like to thank dr. Guan Lim, London, for the pleasant 
cooperation. Maybe our work helped to bring the u.K. a little bit 
closer to the continent. 
De twee voor mij meest belangrijke personen wil ik nog even 
speciaal noemen. Harriet,jij hebt mijn twijfels en zorgen van zeer 
dichtbij moeten meemaken en altijd was je me daarin tot steun.vaak 
was ik vel' weg, diep in gedachten verzonken. Ik hoop dat ik nu, na de 
afsluiting van deze periode, ook geestelijk weer meer bij je zal zijn. 
Dan, iemand die mij thuis vaak bij mijn schrijf- en rekenwerk heeft 
bijgestaan, wiens niet te evenaren adviezen ik altijd graag ter harte heb 
genomen, en die de zon, die ik achter mijn computer gezeten niet zien 
kon, binnenbracht met haar lach ". 
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Laura 
Tot slot, het aanta111lensen dat een bijdrage levert aan een onder-
zoek zoals dit is ontzettend groot; daaro11l besluit ik zoals dagelijks vele 
11lalen te horen is op Radio 3:" ... en iedereen die ik vergeten ben." 
182 
CURRICULUM VITAE 
De auteur van dit proefschrift werd geboren op 13 januari 1964 te 
Spaubeek. Na het afleggen van het eindexal1len Gyll1nasil1ln-~ in 1982 
aan de Scholengemeenschap St. Michie! te Ge!een, vervulde hij zijn 
dienstplicht bij de Geneeskundige troepen in Hilversul1l en Oirschot. 
In 1984 begon hij zijn studie Geneeskunde aan de Rijksuniversiteit 
Limburg, te Maastricht. De stu die kende enke!e korte onderbrekingen 
voor stages in het buitenland (Zweden, Kenya). Tijdens zijn co-
assistentschappen werkte hij alsAmbulance-verpleegkundige bij de 
Gemeenschappe!ijke Gezondheidsdienst, te Heerlen. 
Na zijn afstuderen in 1990 werkte hij een halfjaar lang als poort-
arts in het St. Gregorius Ziekenhuis te Brunssum en als docent Ziekte-
leer aan de Centrale School voor Gezondheidszorg te Heerlen. 
Vanafjuni 1991 was hij gedurende 3Yz jaar als arts-onderzoeker 
werkzaam op de afde!ing Inwendige Geneeskunde II van het Acade-
misch Ziekenhuis Dijkzigt te Rotterdam (hoofd Prof.J.H.P.Wilson). 
In deze hoedanigheid fungeerde hij als coordinator en mede-initiator 
van de Nederlandse Multicentrische Primaire Biliaire Cirrose en 
Primaire Scleroserende Cholangitis projecten (Projectleiders: Drs. H.R. 
van Buuren, Prof. dr. S.W Schahn en Prof. dr. G.P. van Berge 
Henegouwen). Onder lei ding van Prof. dr. S.W Schalm en Prof. dr. 
G.P. van Berge Henegouwen kwal1l hieruit dit proefSchrift tot stand. 
Tijdens deze roerige periode verraste hij de burgerlijk stand van zijn 
woonplaats Breda met een huwelijk en werd hij vader van een dochter. 
Op 1 mei 1995 begon hij de opleiding tot internist in het Ikazia 
Ziekenhuis te Rotterdam (opleider Dr. R.J.T Ouwendijk). 
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